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Abstract 
 
Due to the limited time of the monopoly provided by patent protection that is used for recouping the 
R&D investment, pharmaceutical companies focus on keeping time-to-market for new products as 
short as possible. This process is however getting more uncertain, as the outcome of clinical trials is 
unknown and negotiations with authorities have become harder, making market introduction more 
difficult. This dissertation treats the new product introduction process in the pharmaceutical 
industry from an operations perspective. The overarching aim of this dissertation is to improve the 
planning methodology in this critical process. In an empirical study, the process is first analyzed in 
detail, leading to the identification of several gaps in the industry’s current planning approaches. To 
support a set of key operational decisions towards market launch, a model is subsequently 
developed, considering uncertainty and several important industry characteristics. The model is 
used to gain several insights on the use of risk packaging and on keeping time-to-market short. As 
capacity in secondary pharmaceutical production is critical for product availability, a capacity 
planning model for a new drug delivery system is also developed. It captures the ramp-up phase in a 
better way, while considering inventory build up, plant validation and limited shelf life. The 
performance of several ramp-up functions is tested and insights into ramp-up management are 
presented. The dissertation is concluded with showing the new proposed planning structure, 
concluding in the preceding chapters and outlining future research possibilities. 
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Resumé 
 
Grundet den begrænsede levetid på det monopol som patentbeskyttelsen giver og som benyttes til at 
indhente investeringen i forskning og udvikling, fokuserer farmaceutiske virksomheder på at holde 
time-to-market nede for nye produkter. Hele denne proces er dog blevet mere usikker grundet det 
ukendte udfald af kliniske tests og forhandlinger med myndigheder, hvilket besværliggør 
markedslanceringen. Denne afhandling beskæftiger sig med introduktionen af nye produkter i den 
farmaceutiske industri set fra et produktionsstyringsperspektiv. Det overordenede mål er at forbedre 
planlægningsmetodikken i denne kritiske proces. Processen er analyseret i detaljer gennem et 
empirisk studie som fører til identifikationen af flere huller i industriens nuværende 
planlægningsmetoder. Til understøttelse af en række centrale operationelle beslutninger frem mod 
markedslanceringen, udvikles en model, som betragter usikkerhed og flere af industriens vigtige 
karakteristika. Modellen bruges til at opnå indsigt i brugen af risk packaging og på at holde time-to-
market nede. Idet tilstrækkelig kapacitet i sekundær farmaceutisk produktion er en forudsætning for 
produkt tilgængelighed, udvikles også en kapacitetsplanlægningsmodel for et nyt 
medicineringssystem som bedre fanger ramp up af den ny produktionsproces, imens opbygningen 
af lagre, validering af fabrikker og begrænset holdbarhed betragtes. Flere forskellige ramp-up 
funktioner testes og indsigt omkring ramp-up ledelse præsenteres. Afhandlingen konkluderes med 
at vise den ny foreslået planlægningsstruktur, sammentrække resultaterne for de foregående kapitler 
og opridse fremtidig forskningsmuligheder.     
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Chapter 1: Introduction 
 
A pharmaceutical drug is defined by the US authorities as “articles intended for use in the diagno-
sis, cure, mitigation, treatment, or prevention of disease” (U.S. Food and Drug Administration, 
2010a). Most drugs are developed and produced by pharmaceutical companies and the commercial-
ization of pharmaceutical drugs has in the last decade grown into a large industry. In the EU, the 
industry made up 3.5 % of all value added in 2009, while it made up 17 % of industrial R&D in-
vestments (cf. Eurostat via EFPIA (2010b)). Due to the high value of pharmaceutical drugs, the 
industry produces the highest added value per employee. At the same time, annual R&D spending 
on new drugs represent 2.76 % and 1.90 % of GDP for the US and EU, respectively, which are also 
the two largest markets (EFPIA, 2010b). It is vital for pharmaceutical companies to continually de-
velop and launch new drugs as each drug has a limited life cycle.  
 
In this thesis, the new product introduction process is analyzed from an operations management and 
supply chain management perspective. In this first chapter, the industry structure and new product 
introduction process are outlined, before challenges in managing operations during the new product 
introduction process are presented, and several research questions formulated.  
 
1.1. Industry structure 
Despite a series of acquisitions in the past years, the number of companies in the industry is grow-
ing as increased partnering and outsourcing also enable new companies to partake in the develop-
ment and manufacturing of pharmaceutical drugs (Hunt et al., 2011). Some of the principle organi-
zations in the industry and their interrelations are illustrated in Figure 1.1. The principal stages of 
pharmaceutical production are also illustrated. In the following, these organizations and processes 
are briefly described. 
 
Pharmaceutical corporations 
At the center of the industry are the large pharmaceutical corporations, who develop and manufac-
ture pharmaceutical drugs. Developing a new drug is a long, expensive and uncertain process. Most 
drugs fail to ever reach the market as they do not perform as expected or show unfortunate side-
effects. For preserving commercial continuity and to diversify the risk of the R&D projects, compa-
nies always have several different products in the pipeline in different stages of maturity. Managing 
these pipelines is an important strategic issue for the companies and pipeline planning has been de-
veloped to support companies in how to invest in different R&D projects. 
Introduction  
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Figure 1.1: Overview over the pharmaceutical industry. 
 
 The production of pharmaceutical drugs, as described in Bennett and Cole (2003), can be divided 
into two stages; primary and secondary production. Between the stages, inventories are found.  
 Primary production refers to the production of the active pharmaceutical ingredient [API]. Raw 
material is put through a series of chemical processes where liquids are pumped between different 
reactors, transforming the liquids into the desired compounds.  Secondary production consists of 
turning the API into a consumable drug in e.g. vial or pill form. Sometimes more complex drug 
delivery systems are used such as special syringes, inhalers or other devices. After this step the drug 
is packaged and labeled for the specific market where it is intended to be sold. 
 Production is subject to many strict requirements described in a series of guidelines called Good 
Manufacturing Practices [GMP] issued by the Food and Drug Administration [FDA], (U.S. Food 
and Drug Administration, 2010b). These requirements safeguard patients by putting high demands 
on quality and cleaning to avoid (cross) contamination in production. This can however also lead to 
setups in the order of weeks. To reduce the number of setups, long campaigns are used in which 
several batches of each product are produced in succession in primary production. It is not uncom-
mon for an entire year’s demand to be produced in one campaign (Grunow et al., 2003). With many 
different processing steps integrated in large networks, that produce many different products, pro-
duction planning is very difficult and plans are not easy to change. Secondary production has a 
shorter lead time than primary production. API production is usually managed independently of 
secondary production due to the high complexity. API inventory is used to buffer for any demand 
Contract manufacturers
Pharmaceutical corporations
Regulatory authorities
Generic manufacturers
Pharmaceutical SMEs
Raw 
material
Chemical 
processes
Formulation
Finished 
product
Active
ingredient
Drug
Packaging
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variations and act as a natural decoupling point. Secondary production is demand driven, whereas 
primary production is strictly make-to-stock.  
 
Regulatory authorities 
Governmental bodies regulate the industry within one or more countries and hence govern all com-
panies as seen in Figure 1.1. The most influential regulatory body is the FDA in the US, but also the 
European Medicines Agency [EMA] is gaining more influence due to the centralization of regulato-
ry tasks in the European Union. These authorities put up guidelines and regulations for how phar-
maceutical companies should behave. Most noteworthy are the prescribed clinical trials, which re-
quire companies to test their drugs on a sizable population in a controlled manner such that the effi-
cacy of the drug can be proven and any possible side effects discovered.  
 To protect the public, the authorities also issue the GMP guidelines that govern how production 
should be handled in a clean, safe and controlled manner. To gain access to a market, the local au-
thorities have to validate production before a drug can be sold in that market. Afterwards they will 
regularly perform inspections of production sites to ensure the guidelines are still followed. For 
every market, a possibly different authority gives the final market authorization after reimbursement 
levels, maximum price etc. have been negotiated. 
 
Generic manufacturers 
When the patent on a drug expires, generic manufacturers are quickly ready with cheap copies, 
which drive the price down. Hereafter the drug can be considered a commodity. Drugs that go off-
patent are often transferred to the big pharmaceutical companies’ own generic divisions, so the 
pharmaceutical division can focus on new drugs. Generic manufacturers launch a high number of 
drugs every year, and much of the methodology that we develop here is also applicable for them.  
 
Pharmaceutical SMEs 
Referring to small and medium sized enterprises [SME], this group of companies are normally only 
capable of either performing services for the large multi-national pharmaceutical companies such as 
offering e.g. pilot plant capacity for prototype batches or perform the first steps of drug develop-
ment. The price of running the clinical trials are often so high that these companies have to partner 
up, when they have a drug ready for later stages of the clinical trials. Generally, different levels of 
partnering, outsourcing, mergers and acquisitions are found in the industry as all companies con-
stantly try to balance their R&D pipeline of new potential drugs.  
 
Introduction  
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Contract manufacturers 
This group of companies run production sites and sells their capacity to the pharmaceutical compa-
nies for a premium. This option of outsourcing some volumes or even entire processes, gives the 
pharmaceutical companies the flexibility they otherwise lack in their rigid production systems. A 
comprehensive treatment of the interactions between these companies and coordination of their op-
erations is presented in Boulaksil (2010). 
 
1.2. New product introduction process 
 
Figure 1.2: Overview of the new product introduction process (inspired by (FDA, 2004). 
 
The new product introduction process is the process stretching from first discovery to market launch 
and covers developing, testing and manufacturing a new product (cf. Figure 1.2). After first discov-
ery, a patent is filed. Hereafter follow pre-clinical studies to test toxicity of the drug, before it is put 
into a series of human trials called the clinical trials. These tests should prove whether the drug 
works as intended without too many adverse side-effects. If so, the drug will be approved and can 
be marketed with a monopoly provided by the patent protection. If not, the drug will never reach the 
market and the entire investment in trials and R&D is lost. A more thorough review of this process 
and all the different tasks herein will be presented in chapter 2. One set of clinical trials is enough 
for applying for approval with authorities in several countries, given that the trials comply with the 
standards set by each authority. Due to the cost and length of the trials, companies seek to do only 
one set to cover all markets.  
 Another regulatory task, which is often performed by different authorities, is giving the final 
market authorization after concluding the reimbursement negotiations with the companies. In these 
negotiations, maximum price and reimbursement level are settled. Claims used in the labeling of the 
drug to describe e.g. side-effects and target patient groups are also discussed. For too strong claims, 
the authorities can withhold market authorization. The reimbursement negotiations are conducted in 
very different ways in different countries (Garattini et al., 2007). Especially the procedures in the 
EU are long and troublesome (Cohen et al., 2007). Prices are also set differently, based on e.g. 
comparisons of price and reimbursement levels in other countries, production and R&D cost, or 
results from cost-benefit analyses. The negotiations are important as the reimbursement often co-
vers most of the patients’ expenses for the treatment and because many countries only allow drugs 
Discovery & 
patent filing
Pre-clinical 
trials
Clinical trials
Approval and 
launch 
preparations
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with such an authorization to be prescribed by general practitioners (Cook, 2006). Getting the mar-
ket authorization is hence a prerequisite for gaining any demand in that market.  
 
1.2.1. Trends and challenges 
For some years, the new R&D projects in the pharmaceutical industry have been getting increasing-
ly expensive due to ever harder requirements set by the regulatory authorities for proving better 
efficacy than existing treatments (DiMasi and Grabowski, 2007). They also take longer and are less 
likely to return a sellable drug afterwards (DiMasi, 2002). OF 10,000 compounds screened, 250 
enter pre-clinical trials and 1 drug eventually reaches the market (PhRMA, 2012). Thus, R&D pipe-
lines are no longer thriving with an abundance of potential blockbuster drugs (Hunt et al., 2011). As 
generic manufacturers launch cheap copies after patent expiration, companies have to be good at 
developing their drugs fast, if they want to use the exclusivity of the patent protection for recouping 
their investment and turn a profit. Time-to-Market [TTM] is therefore a key measure for them.  
 Getting a market authorization for a new drug is also getting harder. According to EFPIA 
(2010a), it takes more than 100 days from drug approval to the drug is available to patients in most 
European countries. With the latest financial crisis and ensuing pressure on national budgets, the 
payers of the medical treatments have become increasingly price conscious (Hunt et al., 2011). This 
has and will lead to even harder reimbursement negotiations as the responsible payers attempt to 
push for lower prices. A process which used to be automated (particularly in Germany and the UK) 
is hence now getting longer, more demanding and above all more uncertain. Pharmaceutical com-
panies are forced to spend an increasing amount of time and resources on these negotiations as seen 
by the creation of market access departments in many companies (Von Arx and Bernard, 2009). 
Due to the new EMA procedure with mutual recognition, the reimbursement negotiations are the 
only place where national authorities can influence which drugs enter their market.  
 
1.3. Operations during new product introduction in the pharmaceutical industry 
With a time-limited monopoly to recoup the investment, the price of most novel drugs needs to be 
much higher than the production cost. This creates a lot of pressure on the supply chain operations, 
which has to deliver the product no matter what (Pisano, 1996). With API inventory working as a 
decoupling point, balancing supply and demand is strictly a matter for secondary production. With a 
divergent product flow and limited shelf life, production up front of large volumes is not desirable. 
Figure 1.3 shows the main operations carried out towards market launch of a new drug. The new 
product strategy - partly dictated by the approval and market authorization process - describes the 
sequence in which markets are entered. Markets are usually chosen based on their profitability and 
size. Due to their value and size, EU, US and Japan are entered first. For the rest of the world, 
launch comes at a later stage, when and if it is profitable. Aggregated demand expectations are used 
for capacity planning to generate a capacity promise for the tactical level. Capacity planning for 
Introduction  
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secondary production consists of finding or expanding capacity in a global network while consider-
ing several industry characteristics such as validation and limited shelf life.  
 Demand during market launch varies a lot due to slow product diffusion (Cook, 2006) and time-
phased market launches. Right after the final market authorization has been given, companies rush 
to fill the downstream supply chain, i.e. hospitals, pharmacies and wholesalers, which requires a 
significant volume of finished product at market launch. Demand planning updated with results 
from the market authorization forms the basis for material requirements planning [MRP]. In addi-
tion to production plans, MRP also finds the volumes to procure from suppliers and send to out-
source to contract manufacturers. On the operational level, production and demand fulfillment re-
semble similar processes as found in other industries. 
 
 
Figure 1.3: Overview of the operations leading up to and during the market launch in the phar-
maceutical industry. 
 
 Traditionally, companies have focused on following regulatory guidelines, while insuring ample 
supply at the lowest cost towards the end of the new product introduction process (McKinsey, 
2011). With more uncertainty towards final market launch, coordinating supply chain operations in 
the later stages of the new product introduction process are becoming increasingly challenging. This 
especially affects the decisions which have to be made further in advance. Due to the long and rigid 
production process, API volumes have to be planned well before market launch. The capacity to 
reserve at suppliers and contract manufacturers is also needed.  
 To ensure product availability, secondary production must be ramped-up before product launch. 
Ramp-up effects are especially evident if a new complex drug delivery system is introduced. A new 
product requires new processes that first have to be learned by workers, which reduces the effective 
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capacity leading up to market launch. With highly varying demand during market launch and un-
derutilized production lines, managers do not know the effective capacity of their production lines. 
Only by capturing these ramp-up effects can capacity planning ensure product availability without 
excessive investments in capacity. 
 The connection between new product introduction and supply chain management is simply not 
covered by the existing literature (Narayana et al., In press). Instead completely new methodologies 
are needed to help managers plan operations during the final stage of new product introduction. 
 
1.4. Research objectives 
The overall aim of this thesis is to provide a planning methodology for planning operations in the 
new product introduction process in the pharmaceutical industry, which would keep TTM, risk and 
operating costs low and help companies retain profitability. This planning methodology will be de-
veloped based on existing operation management and planning methodology combined with indus-
try-specific characteristics. A thorough analysis of the new product introduction is offered to find 
the challenges of the industry. Following the analysis, the scope of the thesis is focused on opera-
tions in the last part of the new product introduction process leading up to market launch. Here there 
seems to be insufficient literature addressing coordinating and planning operations leading up to 
market launch which also considers highly varying demand.  
 
1.4.1. Research questions 
Despite having the entire pharmaceutical industry focusing on TTM and the new product introduc-
tion process, it is still not clear what problems the industry is faced with, which have not been ad-
dressed yet, or to what extend the existing literature provides any solutions. A thorough explorative 
study and an overview of the current state-of-the-art are hence required to identify the challenges in 
the new product introduction process. All significant characteristics of the tasks in the new product 
introduction process, their mutual relation must be identified to highlight the challenges in coordi-
nating these tasks. The investigation of the literature should identify how these problems have been 
addressed so far and uncover potential research gaps. This motivates the first research question.  
 
 
 
 Due to the current regulatory trends, more uncertainty of when and under which conditions com-
panies can market their new pharmaceutical drugs is making operational planning of the market 
RQ1: What are the challenges facing the pharmaceutical industry during the new product 
introduction process in reducing time-to-market? 
Introduction  
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launch more difficult. Demand for a new product varies significantly after launch due to product 
diffusion and filling of the downstream supply chain. With several time-phased market launches 
expected, it is difficult to identify the required volumes of finished product. However, several deci-
sions must be made in preparation of the market launch. A certain volume of API must be pro-
duced, packaging material bought, and capacity reserved at contract manufacturers. The need for a 
methodology supporting launch preparation decisions leads to the second research question. 
 
 
 
 Due to the high profit margins on novel pharmaceutical drugs under patent protection, produc-
tion managers must deliver sufficient quantities of the product at market launch. With shorter con-
struction time of new production lines, capacity planning of secondary pharmaceutical production 
can be conducted after the outcome of the clinical trials is known. As secondary pharmaceutical 
production exhibits significant ramp-up effects especially for more complex drug delivery systems, 
capacity planning is no longer trivial. Slow demand diffusion, time-phased market launches and the 
production of small volumes for validation well before market launch leaves production lines un-
derutilized at times. As the ramp up of effective capacity is a result of the experience gained from 
producing a new product, traditional time-dependent ramp-up functions causes an overestimation of 
the effective capacity. Additionally, unique to secondary pharmaceutical production, several tech-
nical requirements such as process validation and limited shelf life must be considered, such that the 
market launches are not delayed due to capacity limitations. This challenge is outlined in the third 
research question. 
 
 
 
 By answering these research questions successively in each of the three publications collected in 
this thesis, the foundation for a planning methodology to support decision making in pharmaceuti-
cal supply chains during the late phase of the new product introduction process will be laid.  
 
RQ2: How can pharmaceutical companies better plan operations in preparation of market 
launches while considering some of the unique uncertainties present around the launch? 
RQ3: How should pharmaceutical companies plan secondary production capacity to reflect 
ramp up of effective capacity on underutilized production lines such that product availability at 
market launch is ensured?  
  Chapter 1  
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1.4.2. Thesis outline 
To answer the first research question, an empirical study is conducted to find the current challenges 
in new product introduction. This is done through a literature review, an extensive case study of one 
company, and several validating interviews with other companies to confirm the findings. From the 
empirical study, a project network representation and a precedence relationship graph of the central 
tasks in the new product introduction process are found. From both the literature review and the 
interviews with managers, insights into the key unaddressed challenges facing the industry are 
found. Two key observations form the basis for the research in the remainder of the thesis. The re-
sults of this study can be found in chapter 2. 
 Coordination of operations in preparation of new market launches is challenging considering the 
many uncertainties associated with market launch of a new pharmaceutical drug. In chapter 3, we 
investigate how to support launch preparation decisions by proposing a model that captures all stag-
es of secondary pharmaceutical production. Uncertainty is treated via two-stage stochastic pro-
gramming, since the problem structure can be used to reduce the problem size, eliminating the need 
for a multi-stage model. The model is demonstrated through a case study to support the market 
launch decisions. Insights on TTM and risk packaging levels are found from comparison of several 
different supply chain configurations and operations policies.  
 A method for modeling ramp up of effective capacity on underutilized production lines is devel-
oped in chapter 4 and demonstrated for capacity planning of secondary pharmaceutical production. 
To ensure product availability, a methodology for when to install and ramp up new production lines 
is developed. With large demand variations during product launch, production lines might not be 
fully utilized. Ramp up is instead captured more accurately by linking effective capacity to cumula-
tive production volume. Furthermore, technical restrictions such as validation of production for the 
individual markets and limited shelf life are considered. We compare our volume-dependent ap-
proach to traditional time-dependent ramp-up functions. Finally, we develop insights into ramp-up 
management by comparing different ramp-up curves and the length of ramp ups. 
 In chapter 5, conclusions for the entire dissertation are gathered and further research areas are 
identified.  
 
1.4.3. Included publications 
The following chapters are all individual publications that are published or under review. They can 
each be read separate, which may cause some overlap. Combined, they provide a methodology for 
supply chain planning in the last phase of new product introduction for the pharmaceutical industry. 
The chapters have been published or submitted as: 
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Chapter 2: Hansen, K. R. N., Grunow, M. (2010). Challenges in shortening new product 
introduction in the pharmaceutical industry. Proceedings of the 17th International Annual EurOMA 
Conference, 6-9 June 2010. 
 
Chapter 3: Hansen, K. R. N., Grunow, M. (2013a). Planning operations before market launch for 
balancing time-to-market and risks in pharmaceutical supply chains, submitted for publication in 
International Journal of Production Economics 
 
Chapter 4: Hansen, K. R. N., Grunow, M. (2013b). Modelling ramp up in the context of secondary 
pharmaceutical production, submitted for publication in International Journal of Production 
Research 
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Chapter 2: Challenges in the new product introduction process in 
pharmaceutical industry 
 
This chapter is an extension of the article published as: 
Hansen, K. R. N., Grunow, M. (2010). Challenges in shortening new product introduction in the 
pharmaceutical industry. Proceedings of the 17th International Annual EurOMA Conference, 6-9 
June 2010. 
 
Abstract 
A patent is the only protection the drug developing pharmaceutical companies have against more 
cost efficient manufacturers of generic drugs. As the drug’s lifecycle effectively end with the 
expiration of the patent, drug developing companies are forced to utilize the effective protection of 
the patent by focusing on shortening development time of new products measured as Time-to-
Market. But due to the uncertainty of drug approval caused by the negotiations with the regulatory 
authorities, investment in initiatives for reducing Time-to-Market should also consider the risk of 
the drug being rejected or the approval being delayed. In this paper the process of introducing a new 
product in the pharmaceutical industry is considered and the trade-offs which both the industry and 
the scientific community have to address in the future are identified. This is done through a case 
study, which identifies the tasks involved in the new product introduction process and analyzes their 
interdependence. The current state-of-the-art in the scientific literature is reviewed and a series of 
observations from the case study are made. This results in an identification of the major focus areas 
for reducing Time-to-Market. 
 
2.1. Introduction 
The pharmaceutical industry develops and produces drugs for alleviating illnesses. The most 
significant activities in the industry consist of drug development, production of the active 
pharmaceutical ingredient called primary production and production of the drug distribution system, 
e.g. vials or pills called secondary production. Companies in the industry can perform any number 
of these activities in different organisational constellations. Lately, increasingly more elaborate 
collaborations and partnerships have emerged. Looking aside from the plethora of small companies, 
which are not capable of developing and manufacturing their own products, the industry can be 
divided into two groups of companies; drug developing companies and manufacturers of generic 
off-patent drugs. In this paper attention is given to the large companies developing and 
manufacturing novel pharmaceutical drugs.  
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Developing and launching a new drug cost a significant amount time and money, since new 
drugs have to go through series of clinical trials prescribed by regulatory authorities. These trials 
consist of testing the drug on a large number of patients and monitoring their reaction to the drug, 
while using other patients given a placebo as a reference group. The trials should prove not only the 
efficacy of the drug, but also find possible side effects and the pharmacokinetic properties of the 
drug etc. Each country has its own authority, which need to approve the drug. Best known is the 
FDA in the US. In Europe there are three ways of getting an approval. Either the authorisation is 
coordinated by the EMA, which forces approvals in one member country to apply in another. 
Alternatively, the company can try to get the drug approved in one country and thereafter use 
mutual recognition for getting the approval in other countries or the company can just get it 
approved in each individual country (Davis, 2003). Common for all authorities in all countries is, 
that they need to approve the drug before it can be sold in the respective countries. Depending on 
the results of the clinical trials they may approve the drug, reject it or require more trials or other 
changes thereby delaying the launch of the product.  
The development of a new drug requires significant capital investments, has a high risk of failure 
and takes many years to complete. According to DiMasi (2002), the average cost is 802 million 
US$ for developing a new drug, which has a 21.9 % chance of getting through the process and takes 
11.9 years to develop. The price has since this study surpassed one billion US$. Hence, it is most 
often large pharmaceutical companies or groups of smaller companies who enter this process. The 
risk is worth running, since the patent protection of the drug offers a time-limited market monopoly. 
Patents last for 20 years and are normally filed after the discovery of the drug. As 11.9 years are 
spent on developing it, only 8 years of effective market monopoly are left. When the patent expires 
cheaper generic substitutes are readily available and sales suffer as a consequence. Getting the new 
drug into the market sooner thereby making better use of the patent protection is the best way for 
the developing companies to increase the total lifecycle revenue of a drug. Therefore 
pharmaceutical companies are focusing their efforts on reducing the Time-to-Market of their new 
drugs.  
In the next section the research questions are outlined followed by a description of the research 
methodology. A case study carried out in a drug developing company is described, which is used to 
analyse the activities involved in the new product introduction process. This results in a project 
network, which shows the structure of the process. Afterwards the literature and its relation to new 
product introduction process are described and finally a series of observations from the industry are 
presented, which could inspire future research. 
 
2.2. Research question and methodology 
To answer the first research question, RQ1, an overview of the new product introduction process as 
it is perceived by practioneers and treated by researchers, is needed. This should also lead to 
observations and further research. Hence, the first research question is split into the following 
subquestions. 
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Research Question 1a [RQ1a]: 
What major tasks are involved in the new product introduction process in the pharmaceutical 
industry and how are they interrelated? 
 
The aim is to define a generic set of tasks including precedence relationships for identification of 
the critical activities. This identification is done on the basis of a case study plus interviews from 
several other companies to check the validity of the case study. The next step is to consider what 
previous work has already been reported in the scientific literature. 
 
Research Question 1b [RQ1b]: 
How does the scientific literature cover the challenges in new product introduction process for 
the pharmaceutical industry? 
 
The central question, which remains to be answered relates to how the TTM can be improved 
and which processes to focus on. During the interviews with managers, a series of observations 
were made, as to which challenges remain to be addressed for the benefit of practioneers and 
scientists alike. 
 
Research Question 1c [RQ1c]: 
Which tasks have to be addressed to reduce Time-to-Market for the entire new product 
introduction process? 
 
2.2.1.  Sample selection 
The main data input for this article comes from a series of interviews done with managers from the 
industry. Due to the large size of pharmaceutical companies and number of people involved in the 
new product introduction process, managers from a variety of functions such as R&D, Production, 
Supply Chain functions, Regulatory Affairs and Marketing have been interviewed to obtain a 
complete picture of the process. Only from one company, the case study company, have all 
managers in all these positions been interviewed. This case company forms the centre, but as stated 
in Eisenhardt (1989), more cases are needed to prove generality and validity. This has been 
achieved through control interviews for all management functions at 8 other companies. 
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The involved companies are all located in the greater Copenhagen and Malmo area in Zealand, 
Denmark and South Sweden. This area is known as Medicon Valley for its high density of 
pharmaceutical and biotech companies. These companies were chosen in part due to their 
geographical location close to the university and in part for their willingness to participate in the 
interviews. 
 
2.2.2. Interview protocol 
As the nature of this project is exploratory, semi-structured interview were chosen. In this interview 
form, a structured list of questions is prepared in advance. But during the interview the interviewer 
can skip some questions and go in depth with others, depending on how the interview evolves. This 
is suitable as it helps keeping track of the interview, while allowing the interviewer to explore 
interesting new statements offered by the interviewee (Bakeman and Gottman, 1997). Since most 
managers’ working knowledge of the involved planning and execution of tasks in the new product 
introduction process was normally confined to a few tasks within their own responsibility area, it 
made no sense to spend much time on probing for answers outside their respective area of interest. 
After a short discussion of the managers’ responsibility area, he/she was asked to identify 
important tasks in the new product introduction process and point to major bottlenecks and 
problems in the process. This was done on the basis of a project network structure, which was 
iteratively developed throughout the interviews. With this information it was also possible to find 
the tasks that prolong the market introduction and lead to an unnecessarily high TTM.  
Afterwards questions to all tasks in the process were posed and the manager answered as best 
he/she could. This served to establish knowledge of the tasks the manager worked with or was 
responsible for and observations of weak practices were made.  
 
2.2.3. Data collection 
All the interviews were conducted from December 2009 to March 2010 and in all 18 managers from 
9 companies have been interviewed. All interviews were digitally recorded for later use and 
sketches of how to improve the project network were gathered from the interviews. Validity and 
reliability was ensured by having control interviews for each manager position type as mentioned in 
‘Sample Selection’.  
 
2.3. Case Study 
The case study builds on interviews and information gathered from a pharmaceutical company, 
which for confidentiality reasons shall remain nameless. The company is a drug developing phar-
maceutical company, which develops and manufactures a range of APIs and final drugs. All drugs 
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are of similar chemical structure and are produced at several multi-purpose batch plants in Europe. 
The R&D organisation including a pilot plants use up more than 20 % of the annual revenue. In all 
8 managers from across the organisation were interviewed such that the complete new product in-
troduction process in the company was covered.  
The new product introduction process is organised in a matrix structure, which, as became 
apparent from interviewing the other reference companies, is commonly used in the industry. After 
the development of a series of new compounds, the most promising candidates are chosen to be 
further developed and get assigned to a development team. The development team consists of 
specialists from the different functions in the company i.e. production, R&D, marketing and 
regulatory affairs. The team’s composition depends on the stage in the new product introduction 
process of the drug. Marketing or pharmacoeconomists are involved in the beginning and end of the 
process to evaluate economic feasibility and prepare forecasts. Production and Supply Chain 
managers are increasingly involved, the further along the project proceeds, starting during capacity 
planning and the design of the production process. Under the responsibility of the R&D department, 
the production of prototype API for the clinical trials is done in the pilot plants, which are not 
intended for large scale production. Both R&D and Regulatory Affairs are involved all the way 
from conception of the drug to final approval. Decisions on whether to continue the development of 
the drug are taken on revision meetings with the top management. 
 
 
Figure 2.1: Project network representation of the new product introduction process. NB: Task 
length does not represent task duration. 
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2.3.1. Identifying the project network 
During all interviews, a project network of the new product introduction process was presented and 
each interviewee was then asked to suggest changes in how they perceived the project network 
structure. Through this iterative process the project network seen in Figure 2.1 was created. The 
project network involves three key functions in the company (R&D, Production and Commercial) 
and those activities carried out by the Regulatory Authorities. The length of the tasks in Figure 2.1 
is not indicative of the task lengths or the resource consumption, but helps indicating the timeline in 
the process from patent filing to patent expiration. 
 
The tasks of the Regulatory Authorities are found at top of the network. R&D and Regulatory 
Affairs make up the R&D category. Here the first main task is the conception or discovery of the 
drug itself (cf. the Discovery task). It is at this time the application for the patent is filed and the 
patent life starts (cf. the filing and expiration events). Next, initial studies of the drug are made in 
the pre-clinical trials (cf. the PC task) to test its toxicity. Based on the animal experiments in the 
pre-clinical trial, the documentation is sent to the authorities, here illustrated for the FDA, for re-
view (cf. the first R task) as an Investigational New Drug application [IND]. If it is approved, the 
company can start the clinical trials (cf. the C1-C3 tasks). After these have been completed, docu-
mentation is sent as a New Drug Application [NDA] (cf. the event NDA) for a final review (cf. the 
second R task). The drug can either be completely rejected, completely approved or the authority 
can request more data thereby delaying the approval. This will require the company to respond to 
any comments from the authority and possibly produce the requested data (cf. task RR) before final 
review and the approval can be given (cf. the task R and the event Approval). A final clinical trial 
may also be needed after the approval of the drug, if the authorities or company sees the need for 
one. This could for instance be to try the drug on smaller patient segments such as children or preg-
nant women. Finally, drugs particularly important in curing previously incurable diseases can gain 
fast track status (cf. Fast-track approval) where requirements are temporarily lowered. Though the 
authorities’ requirements are difficult to live up to, they are generally clearly stated as guidelines. 
The uncertainty of approval arises from the company’s interpretation of whether observed effects in 
the patients are statistically significant. The uncertainty is a clear risk for all tasks carried out paral-
lel to the clinical trial. If a trial fails, the prepared capacity become idle and work on other tasks 
become worthless. In the worst case the entire drug is abandoned or rejected and the company has 
nothing to show for its investment. 
The production of prototype batches in pilot plants for the clinical trials (cf. the Prototype Batch 
Prod. task) is in some companies a R&D task and a production task in others. Production and sup-
ply chain functions are much stronger involved during the design of the production process (cf. the 
Process Design task) which is done simultaneously with the clinical trials. Depending on the pro-
duction method and current capacities, additional production resources may have to be made avail-
able (cf. capacity preparation). This could either be by clearing capacity at existing production lines 
or by expanding production facilities with new equipment or even new factories. The reason capaci-
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ty preparations are done in advance of the process design is that it may take that a long time to find 
equipment by phasing out old products or build a factory. For the case company all production pro-
cesses are so similar, that the same equipment is used, in what is called multipurpose batch plants. 
Process design is often more process tweaking than fundamental redesign. This relation between 
capacity preparation and process design may be different for other companies. The production of 
the drug then starts before the approval is granted, since three high quality and identical batches 
have to be produced for the authorities as part of the NDA (cf. the Production task). Furthermore, 
API inventories are normally filled before the market introduction (cf. the launch event) in order to 
fill up the market immediately after market access has been gained. The production continues until 
the drug is either removed from the market or moved to generic production, which happens some-
time after patent expiration. 
In addition to forecasting and promoting the sales volume (cf. the Sales task), commercial tasks 
involve economical assessments of a drug’s potential early in the process (cf. the Eco. Ass. task) 
and in preparing the entry into new markets (cf. the Market Access task). The latter task consist of 
further identifying the economic benefit of entering the country or market, but also of planning and 
conducting negotiations with local authorities to secure subsidies to patients; reimbursement. As 
new approvals and reimbursement have to be negotiated for each authority, this process is repeated 
in each country or market for each drug; hence the cascade in Figure 2.1. 
The remaining tasks involved in new product introduction are not shown here, partly since they 
consist of traditional tasks also found in other industries and partly because they are considered par-
allel to production such as procurement and distribution. It is important to note, that TTM is meas-
ured from the patent filing to market launch of the drug. The precedence relationship identified 
through the interviews can be seen in Figure 2.2 illustrated as a directed graph going from drug dis-
covery and patent filing to finally patent expiration and product removal. Interactions with the regu-
latory authorities are not shown.  
All the interviewed managers pointed to the clinical trials as the major bottleneck in the process. 
In addition it was mentioned, that several managers’ main responsibility was to keep their task off 
the critical path i.e. to not delay the process. After gaining the approval, it would either be the sub-
sidy negotiations or production that would slow the product launch. As the project network in Fig-
ure 2.1 has been created and the precedence of the tasks set in Figure 2.2, RQ1a has been answered. 
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Figure 2.2: The identified precedence relationship illustrated as a directed graph. 
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2.4. Locating literature in the project network 
The review only covers literature for prescriptive and quantitative planning methodology. As can be 
seen in Figure 2.1 marked with three dotted boxes, previous contributions in the literature have ad-
dressed managing and planning some of the tasks in the new product introduction process. The box-
es are here drawn around the main tasks, they provide decision support for. Most of these areas 
have come from process system engineering community. Shah (2004) reviews supply chain contri-
butions for the pharmaceutical industry more directly. Here the current trends in the pharmaceutical 
industry are listed, which are all relevant for the new product introduction process. The trends in-
clude fewer potential research compounds, shorter effective patent protection, more generic substi-
tutes and more price focused customers and authorities. The main contribution of Shah (2004) is a 
classification of the major areas found in the literature for the pharmaceutical industry: 
 Pipeline management or planning 
 Capacity planning 
 Simultaneously pipeline and capacity planning 
 Production planning and scheduling 
 Process development and plant design 
 Supply chain simulation 
There is given no relation to how these planning areas relate to the observed trends. Only first 4 
planning areas are really interesting in the new product introduction context as can be seen in Figure 
2.1. Pipeline planning is the discipline of planning which products in the pipeline to develop further 
in the face of uncertainty from the approval. Schmidt and Grossmann (1996) were the first to ad-
dress this problem. It has since then been followed by Jain and Grossmann (1999), where the au-
thors are the first to also schedule the development tasks with limited resources. Since then, several 
contributions have proposed other approaches for pipeline planning. Two-stage stochastic pro-
gramming is used in Colvin and Maravelias (2008), where the authors use non-anticipatory con-
straints to manage the scenario structure. Later, the authors focus on developing a branch and cut 
algorithm (Colvin and Maravelias, 2010) and consider task interdependencies (Colvin and 
Maravelias, 2011). Real-options-based planning is used by Gupta and Maranas (2004) and Perez-
Escobedo et al. (2012) address pipeline planning with multi-objective programming. This body of 
literature does support managing the R&D portfolio while considering uncertainty and it does seem 
to provide a good trade-off between TTM and risk. 
Rotstein et al. (1999) are the first to investigate the impact of production cost and available ca-
pacity on profitability. Papageorgiou et al. (2001) extend their MILP model to capture the business 
structure of a pharmaceutical company and consider several practical constraints. But their model 
does not account for the uncertainty resulting from the clinical trials. This is addressed by Gatica et 
al. (2003), which use two-stage stochastic programming approach to capture both failure in the clin-
ical trials and different demand scenarios. Both uncertainty and business structure are captured by 
Levis and Papageorgiou (2004), who also introduce an effective heuristic for solving the problem. 
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Maravelias and Grossmann (2001) combine the pipeline planning problem and capacity planning 
problem and solve them jointly via decomposition.  
Production planning is arguably also related to the new product introduction process, since the 
above mentioned models include some production planning elements, but only on very aggregate 
level; usually annual quantities. More specific mentioning of production planning has not been 
found in relation to new product introduction. Nor is the new product introduction mentioned in 
Méndez et al. (2006) or Shaik et al. (2006), the two most commonly cited review papers on produc-
tion planning in this field. For the pharmaceutical industry, several sites and products for each com-
pany and especially the long setup times quickly make production planning intractable. Campaign 
planning, in which several batches are produced per setup, has been developed for the pharmaceuti-
cal industry to provide a production planning methodology (Grunow et al., 2002). With the use of 
cascades and heuristic approaches, industrial size problems can be solved (Grunow et al., 2003). 
While these and many other contributions try to schedule chemical product in an effective way, 
little attention is given to secondary production due to the less complex processes. Stefansson and 
Shah (2005) is one of the few contributions. Here different levels of data availability for fluctuating 
demand are treated.  
 Due to the large supply networks of pharmaceutical companies, supply chain management has 
recently been given attention. Sousa et al. (2008) develop two models for tactical and operational 
planning, which they propose solving in succession. They test their approach on a case from the 
agrochemical industry, which is similar to the pharmaceutical industry. They extend their work in 
Sousa et al. (2011), where an industrial sized problem is solved by developing two decomposition 
approaches with fast solution times and good solution quality. Supply chain issues are addressed in 
Laínez et al. (2009), where the main topics are capturing financial aspects, the integration of cus-
tomers and suppliers and managing risk. Though their work is not industry specific, the pharmaceu-
tical industry is given separate mentioning by a review of the capacity and pipeline planning litera-
ture. Susarla and Karimi (2012) focus on the coordination of a global supply chain by considering 
supply network planning with tariffs and transfer prices. They cover the entire supply chain of a 
company while considering all tasks and yet achieve good results with the use of a heuristic ap-
proach. Though the supply chain issues described are relevant, none of the contributions relate their 
work to the introduction of new products. 
When looking for literature on reducing the TTM, only a small fraction is suitable for the phar-
maceutical industry. In a review, Krishnan & Ulrich (2001) found several contributions to opera-
tions during the new product introduction process. A central problem is that of market launch tim-
ing, which trade-offs the value of additional development time for better products with lost market 
share due to delayed market launch (Cohen et al., 1996). With a time-limited patent on new drugs, 
market launch timing in the pharmaceutical industry is not a problem. Another stream of literature 
extending the original Bass or product diffusion model with operational constraints is described in a 
review by Mahajan et al. (1990). The aggregation level in these contributions is however too high as 
the full life cycle of products is considered and production is overly simplified. They do hence not 
provide decision support for the challenges facing managers in the pharmaceutical industry. Two 
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contributions have been found, which treat do operations during new product introduction in phar-
maceutical supply chains specifically. Gjerdrum et al. (2001) use a simulation approach to see the 
effect of introducing a new product on other products in a pharmaceutical supply chain. Similarly, 
Sundaramoorthy and Karimi (2004) proposes a model for testing if a new product can be incorpo-
rated into an existing multi-purpose batch plant or if some processes must be outsourced. No contri-
butions have been found by the authors, which aim at reducing the TTM by effectively managing 
the operations involved in the new product introduction process. 
 Uncertainty within planning is a huge issue for the process industry in general (Papageorgiou, 
2009). Shahinidis (2004) review a series of techniques for modeling uncertainty. The use of robust 
optimization to manage risk inspired by Mulvey et al. (1995) is given particular focus. Tsang et al. 
(2007b) demonstrates the use of several other techniques such as expected downside risk, oppor-
tunity value, value-at-risk and conditional-value-at-risk on a capacity planning model for the phar-
maceutical industry, which they present in Tsang et al. (2007a). The remainder of the vast body of 
risk management literature is not reviewed further here.  
Considering the literature and its scope, it seems that there is a gap in the methodology for plan-
ning the involved tasks, stretching from the filing of the NDA to market launch. Besides the pipe-
line planning literature, no other contributions address the industry’s demand for a methodology 
aimed at reducing the TTM while simultaneously considering in inherit uncertainty of the clinical 
trials and reimbursement negotiations during this phase. With this literature review, RQ1b has been 
addressed. In the next section, observations from the case study are stated, which highlights the 
challenges in the industry and thereby shows the way for further research, which could contribute to 
reducing TTM. 
 
2.5. Insights from the case study 
All interviewees pointed to the clinical trials as being the major bottleneck for the whole new prod-
uct introduction process. Trying new drugs out on patients, finding and analyzing the results are 
simply lengthy tasks. During the interviews, managers were inquired about the current planning 
techniques used by the company to plan the clinical trials while considering the entire pipeline. The 
interviews revealed a simplistic and pragmatic approach to decision making, which consisted of 
identifying key figures, discussing risk elements and making gut feeling decisions of which drugs to 
allocate which resources for.  
 
 
 
Observation 1: Risk elements seem to be handled with gut feeling and simple measures at 
best. No consistent methodology is employed for pipeline management.  
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Whereas the available planning techniques for the pharmaceutical industry have evolved in the 
literature during the last 10-20 years, it seems the industry has been slow to follow. More focus 
should be given to the implementation of such techniques. This is however beyond the present 
scope.  
In the case company, the Market Access section was involved early in the new product introduc-
tion process as advisors. The reason for this was in part so that they could start preparing the sales 
organization for the launch, but they were also used as consultants in setting up the clinical trials. 
Different authorities in different countries demand different tests and documentation to grant their 
approval. The decision of whether to do certain trials up front to gain faster approval or whether to 
do these later and get the drug out onto a smaller number of markets fast is not trivial. To the best of 
our knowledge this has not yet been mentioned in the literature. 
 
 
 
Research in this area could consist of expanding known pipeline planning models. Two points 
have to be added. First, the planning of the trial sizes is a very complex procedure which involves 
highly complex statistical relations for finding the needed trial population which can prove or dis-
prove a claim. Secondly, there is so much overlap between the requirements of the different authori-
ties, that a one-off trial is normally conducted. It was neither possible to establish how big a poten-
tial gain would come from this, nor what added risk a reduced trial would cause. 
So far only the two most central regulatory authorities have been mentioned, FDA and EMA; but 
there are many more. In Europe only the market approval can be granted through the centralized 
system administrated by EMA. For negotiating the reimbursement, the company has to carry out 
separate negotiations with each member country or possibly each municipality. This leaves a lot of 
negotiations to be carried out. The order in which these negotiations are carried out is decided based 
on a business case made by the company, which considers authority requirements, potential market 
size, potential subsidy and expected negotiation time. As different authorities use different tech-
niques for awarding or evaluating subsidies e.g. comparison to other countries or based on produc-
tion and R&D cost, the order in which these subsidy negotiations are carried out influence the over-
all granted level of subsidies. A higher subsidy leads to higher potential price of the drug and in-
creased sales i.e. higher revenue. This creates a trade-off between scheduling negotiations to either 
obtain higher subsidies or to schedule negotiations such that markets can quickly be accessed. 
Again, the process of scheduling market access negotiations was described as being based on gut 
feeling decisions. 
 
Observation 2: There is no or little attention given to how market expansions and clinical 
trials should be planned simultaneously and what the effect is on the time-to-market.  
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There is no doubt that the industry could benefit from such a model, if it could increase the price 
of a drug in all European countries. The main obstacle with research in this area is the availability 
and definition of data. Finding out how price setting occur and account for variations in outcome of 
the negotiations may prove very difficult. Furthermore, there are large variations in how fast these 
processes are conducted in the different countries and the resource requirements per negotiation are 
not clear.  
In preparation for the launch of a new drug in a market, it is industry practice to build up stock to 
get the drug to the customers as fast as possible, so production will not halt the market launch. Here 
planning with some rules of thumb is widely used e.g. 1 year supply on inventory needed at the API 
stage, a half at the formulation stage and for a quarter of finished products. However following 
these rules in practice may be difficult over time as several dynamics of both the supply chain and 
the market has to be considered. On the supply side, lead times have to be considered in both build-
ing up the inventory and in consuming it around the launch period. The market side is conversely 
uncertain with poor forecasts accuracy and uncertainty in the negotiations. Even planning for a high 
demand scenario alone may not be enough to assure sufficient availability. As an example the last 
part of the approval process often involves forced changes to the label or packaging material, which 
lead to forced scrapping of drugs packaged before the final authorization is granted as repacking is 
not allowed. The decision whether to package the drug up front despite the risk or ‘risk packing’ 
offers the trade-off between potentially saving the packaging procedure after approval and reduce 
the step between approval and launch versus the risk of having to change the label and throw away 
the entire packaged inventory. Throwing the finished drug away is not only expensive, but leads to 
a further delay of the launch if the product has to be produced again. Hence the key decisions that 
need to be supported are finding both production and inventory volumes throughout the supply 
chain.  
 
 
 
Since production and inventory built up in the late stages of the new product introduction process 
can hold back market launch and thereby get on the critical path, managing these process would 
directly contribute to lowering the TTM. Furthermore, in order to cut cost, the authorities are be-
Observation 3: A systematic approach to address the trade-off between negotiating for a 
higher subsidy versus negotiating for a faster market introduction seems to be missing.  
Observation 4: Finding production and inventory volumes leading up to market launch is 
not addressed in the literature nor by the industry. No appropriate method for assessing risk 
packaging has been found. 
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coming increasing difficult to negotiate with and several companies are directing more resources 
towards market access. 
A prerequisite for product availability is capacity availability. Due to the long construction time 
of new sites, capacity planning in the pharmaceutical industry has already been given much atten-
tion as these decisions have to be taken before it is known whether the drug will get approved. With 
this risk, it is often better to postpone as many of the investment decisions for as long as possible. 
Often investments into the production equipment are delayed which also benefits the process design 
department, who gets more time to optimize the processes for a higher expected output. Especially, 
investments in secondary production equipment are postponed as these have shorter construction 
time. The problem is however, that the equipment has to be installed and the process demonstrated 
to the authorities as part of the approval process as well as be used for building up inventory. With 
secondary production exhibiting ramp-up effects, ramp up should also be considered so sufficiently 
high effective capacity can be reached in time. Capacity planning for secondary production is no 
longer trivial. Production managers must ensure product supply does not the cause a delay in market 
entry.  
 
 
 
From the observations made above, it seems that there are several ways to reduce TTM. Not all 
of them appear equally promising. The lack of implemented pipeline planning tools is predominant-
ly an industry problem. Expanding pipeline planning with the trial design elements may prove diffi-
cult as broken up trials require more subjects than one big once-off trial. Developing a planning or 
scheduling methodology for the reimbursement negotiation seems possible; however data access 
and the lack of transparence of the market access process are likely to make this line of research 
virtually impossible. The operational issues of market launch and capacity planning appear to be the 
most approachable issues. Both processes are usually not on the critical path in the new product 
introduction process, but a methodology has to be developed to ensure that remains the case. With 
this conclusion, RQ1c has been answered.  
 
2.6. Conclusion 
In this contribution the new product introduction process in the pharmaceutical industry is studied. 
A case study is carried out, which consists of interviews with several managers in all functions. For 
each function, a validation interview with a manager in the same function in another company is 
made. From the case study a project network is created, which identifies all of the company’s major 
Observation 5: Decision support for capacity plannning of secondary production and the 
consideration of ramp up, which are prerequsites for product availability and on-time market 
launch, has to be developed.  
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tasks in new product introduction. These tasks are then linked to each other in a precedence rela-
tionship chart. The literature is reviewed with a focus on the planning methodology for new product 
introduction in the pharmaceutical industry. Several gaps are identified that can reduce time-to-
market for new products. The final stage of the new product introduction process seems to be par-
ticularly lacking a methodology for managing operations at this critical time. The operations man-
agement literature does not seem to offer any methodology which can directly be applied. From the 
case study, several observations are made about the current planning challenges of the industry and 
the most promising areas for further research are identified. It is clear that better planning of opera-
tions before market launch is needed. 
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Chapter 3: Planning market launch operations in pharmaceutical supply chains  
 
This chapter is based on an article submitted as: 
Hansen, K. R. N., Grunow, M. (2013). Planning operations before market launch for balancing 
time-to-market and risks in pharmaceutical supply chains. submitted for International Journal of 
Production Economics 
 
Abstract 
Research-based pharmaceutical companies are pressed to reduce the time-to-market, since the 
increase in the duration of the drug development process makes it hard to recoup the R&D cost 
while under patent protection. Before a launch, sufficient products have to be available to fill the 
downstream supply chain. Unique for the new product introduction process in the pharmaceutical 
industry are the risks of delayed market authorization and a required change of the used printed 
packaging material. Pushing inventories down in the supply chain may reduce the time-to-market, 
but it also limits the flexibility to react on these risks and may lead to waste when products must be 
disposed due to rejected packaging. We have developed a model for detailed planning of the market 
launch phase, while considering lost revenue caused by delays. Our model finds the needed volume 
of active pharmaceutical ingredient to produce the volume of print packaging material to procure, 
the volume contracted out to external manufacturers plus the production and inventory volumes on 
all echelons in the supply chain to accommodate for all possible launch dates. The authorization 
risks are included directly in our two-stage stochastic model. In order to limit the required 
computational effort, we use the problem structure to keep the number of scenarios low. The results 
from a case study based on a real world setting show that the use of our model can lead to 
significant savings in the cost of launching a new pharmaceutical drug compared to current 
practices. Finally, a model extension is proposed which is based on robust optimization to illustrate 
the cost trade-off in reducing time-to-market. 
 
3.1. Introduction 
3.1.1. Approval, authorization and time-to-market  
All new drugs have to go through a series of clinical trials prescribed by regulatory authorities e.g. 
the FDA or European Medicines Agency [EMA]. Here the efficacy and side-effects of the drug are 
determined and documented (Lipsky and Sharp, 2001). The cost and length of pharmaceutical R&D 
projects are tightening due to increasing requirements for these trials (DiMasi, 2002, PhRMA, 
2012). If the drug is approved by the authorities, the drug can be marketed under the protection of 
the patent. Since patents are filed early in the R&D phase, when promising compounds are found, 
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only a short time remains before the patent expires. As soon as the drug goes off patent, generic 
manufacturers launch similar drugs, which drive the price on the drug down. Hence developers of 
new pharmaceutical drugs have a strong focus on reducing time-to-market [TTM], which prolongs 
the profitable period under patent protection. The importance of TTM is illustrated in Figure 3.1. 
Assuming that the market penetration curve is the same regardless of launch date, a launch at T1 
increases the time under patent protection compared to a launch in T2 and the company thereby 
extends the peak revenue. In practice the peak revenue level may also be lower for a launch in T2. 
The market share may be reduced as competitor products possibly have gained ground during the 
delay. With the approval process lasting 12 years, little time is left for marketing the drug with 
patent protection (DiMasi, 2002). We however only focus on the short period around the market 
launch. Figure 3.1 also shows a surge in demand right after launch. We refer to this as the supply 
chain filling effect, which is caused by extra demand of filling the downstream supply i.e. 
wholesalers, hospitals and pharmacies (Cook, 2006).  
 
 
Figure 3.1: Illustration of the lost peak revenue. 
 
Though much work has been done by the industry to streamline the process of obtaining the 
approval, the process of receiving market authorization has received less attention (Danzon et al., 
2005). Drugs are subsidized by governments and health insurances through reimbursement of (a 
part) of the price. The settling of a reimbursement agreement is effectively a prerequisite for selling 
to a new market. To obtain reimbursement and market authorization, a set of reimbursement 
negotiations with the local authorities has to be carried out, in which, in addition to fixing the 
maximum price and reimbursement levels, labels and leaflets are approved. While the approval 
itself can be conducted centrally in Europe through for example EMA, the authorization process has 
to be carried out locally. A process which in 2010 varied in length from country to country as can 
be seen by the average time between approval and authorization in Table 3.1. 
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Table 3.1: Examples of average time between approval and authorization (EFPIA, 2010a). 
Country Average time in days 
UK and Germany 1 
Ireland 101 
Spain 260 
France 289 
Italy 306 
Belgium 403 
 
In the past years, the health care costs in most western countries have been rising. Especially 
after the latest financial crisis, governments have decided to cut expenditures. This leads to 
reimbursement negotiations significantly longer than the values in Table 3.1 and lower 
reimbursement levels. These new negotiations are a substantial change over the automated 
registration of new drugs, which has traditionally been practice in countries such as the UK and 
Germany. Both the length of the process as well as the reimbursement level are more uncertain 
while profit margins are dropping (Rossetti et al., 2011). This holds for most western countries. In 
2012, for example, the procedure in Germany changed from a one-day automated authorization 
process to a process which lasts up to half a year. However, each day a blockbuster drug is delayed, 
the lost revenue can be in the order of millions of euros. Pharmaceutical companies should therefore 
treat the reimbursement negotiations in a more systematical way (Danzon et al., 2005). There is 
hence a need for improved market launch planning capturing the authorization risks and aiming to 
limit the lost revenue. 
 
3.1.2. Operations planning before market launch  
To further delimit the problem treated in this paper, we use the distinction between strategic and 
tactical decisions in market launch (Trim and Pan, 2005). The relation of market launch decisions to 
other corporate function and planning areas (pipeline, capacity and production planning) can be 
seen in Figure 3.2. On the strategic level, decisions are made on which demographic and 
geographical markets to enter considering (i) regulatory requirements, (ii) demand forecasts, (iii) 
the R&D plans and (iv) the uncertainties of the clinical trials and the approval process. Strategic 
decisions are taken well before a drug is launched and align the product development to the 
company strategy. A misfit here may lead to outsourcing or partnering of the remaining 
development of a drug. While the tactical level in Trim and Pan (2005) refers to marketing 
decisions, we here consider supply chain decisions. 
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To avoid contamination in production, the authorities impose strict cleaning regulations on the 
production equipment. These cleaning requirements lead to long setup times in the order of weeks 
for the production of the active pharmaceutical ingredient [API]. As a result, long campaigns in 
which numerous batches are produced for each setup arise, making API production very inflexible 
(Grunow et al., 2003). These API production plans are largely fixed and cannot be adapted to 
sudden changes. To plan for API production, aggregated API supply volumes and due dates are 
needed in advance. Similarly, the procurement volumes of printed packaging material [PPM] and 
the production volumes outsourced to contract manufacturers [CM] have to be determined with 
some notice in advance due to the lead time of these companies and depending on the contractual 
agreements especially between the outsourcer and contract manufacturer (Boulaksil et al., 2011). 
The final stages of production in which the API is formulated into e.g. pills, put in blister packs and 
packaged must also be considered. Aggregated formulation and blister production volumes are 
needed as these production processes also involve campaign planning, which however has a much 
shorter time horizon than production planning for the API (Stefansson and Shah, 2005). Packaging 
operations can be changed with short notice, but the capacity of the packaging equipment must 
however be reserved up front. All of these volumes are needed as inputs into master production 
planning in secondary production of pharmaceutics.  
The focus of this paper is to plan operations (see Figure 3.2) in the pharmaceutical supply chain 
to build-up inventory prior to market launch such that TTM is kept short, while considering 
uncertain launch dates given the outcome of the authorization process. We focus on the above six 
key decisions, which we will refer to as the launch preparation decisions. These are the required 
API, PPM, CM and formulation and blister volumes and the reservation of packaging capacity 
throughout the planning horizon.  
 
 
Figure 3.2: Scope of market launch and the planning area in new product introduction. 
 
R&D
Operations
Launch
Production Planning
(tactical)
Pipeline Planning
(strategic)
Strategic Alignment
(strategic)
Capacity Planning
(strategic)
Operations Planing
(tactical)
Market Launch
  Chapter 3  
31 
 
3.1.3. Authorization risks 
Three separate risks originate from the authorization negotiations; 1) uncertain length of the 
negotiations, 2) uncertain reimbursement level and price and 3) the risk of a required change of the 
used leaflets and labels (PPM).  
 
1) The length of the reimbursement negotiations can vary significantly. Since the authorities seek 
to cut down expenditures, the negotiations become more difficult and their length hard to 
predict. 
2) In setting and negotiating the maximum price and reimbursement level, the authorities typically 
use different systems for evaluating and assigning these. For example, in the UK a process is 
used, whereby the drug is rated and both maximum price and reimbursement are then given 
without much discussion. Other countries set maximum prices by comparing to reference 
countries or by use of cost-benefit analysis (Garattini et al., 2007).  
3) Authorities can force the pharmaceutical company to change the naming and wording on the 
PPM (referred to as a forced label change). They do so, if they find the text on the PPM 
misleading, e.g. with regard to the claimed benefit, recommended use, side effects or target 
patient group. In this case the company will have to scrap all of their products which are already 
packaged, as repacking is not allowed. Products which are nonetheless packaged before 
authorization is obtained are thus said to have been risk packaged. This may be suitable to 
reduce TTM. 
 
The price of the drug affects the demand of the drug. The uncertainty of the reimbursement 
negotiations therefore inflates the demand uncertainty, which due to the lack of historical data is 
large anyway. For new products, demand forecasts built on estimates created by experts, who use 
the performance of the drug shown in the clinical trials combined with their knowledge of the target 
patient group to forecast demand. Besides an expected scenario, best and worst case scenarios are 
usually identified (Cook, 2006). These demand scenarios depend on the market authorization 
process as the outcome of a cost-benefit analysis made by the authorities dictate how they rank the 
drug and hence how much will be prescribed.  
 
3.1.4. Paper contributions and structure 
The contribution of our work is a methodology for supporting the launch preparation decisions, 
which have to be taken prior to market launch. The most important decisions are the required API 
supply volume, the procurement volumes of PPM and the volumes outsourced to contract 
manufacturers in addition to the formulation and blister production volumes and the reserved 
packaging capacity. We address the trade-off between risk and TTM in launching a new 
pharmaceutical drug by: 
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 Identifying the relevant risks (see above).  
 Proposing a two-stage stochastic MILP model for addressing market launch planning and the 
identified risks in the pharmaceutical industry, including all relevant supply chain echelons and 
using the model structure to keep the model tractable. 
 Testing our modeling approach through a numerical analysis based on a realistic industry case. 
 
This paper is structured as follows. The next section contains a review of the literature on supply 
chain issues relevant for the introduction of new products in the pharmaceutical industry. Hereafter 
follows the problem outline and a description of the scenario modeling in section 3.3, leading up to 
a presentation of the model in section 3.4. In section 3.5, a case study from a large pharmaceutical 
company is introduced and the most important findings are shown in section 3.6. Risk management 
is discussed in section 3.7, before concluding remarks are given in section 3.8. 
 
3.2. Literature review 
Factors that influence the ability of new products to penetrate a market have had the interest of the 
marketing community for a long time. The model introduced in Bass (1969) for forecasting the 
demand of a new product based on estimated market size and on two coefficients relating to 
innovation and imitation has gained widespread popularity. A large body of literature has since 
treated new product diffusion.  Reviews can be found in Mahajan et al. (1990) and Peres et al. 
(2010). Diffusion models and forecasting for market launch planning of a new pharmaceutical drug 
is described in Cook (2006). Here an s-shaped curve is found to describe the market diffusion well, 
though other models for particular slow and fast diffusion are also found.  
As demand fulfillment is constrained by capacity, new product diffusion models have been 
extended to consider capacity expansion, inventory build-up periods and production and sales plans 
for the life cycle of an innovative new product. Jain et al. (1995) were the first to consider limited 
capacity by creating an intermediate group of waiting applicants (interested customers) between the 
potential adopters (the market) and the adopters (served customers). Their extended Bass model was 
applied to an Israeli phone company with a monopoly, while assuming none of the waiting 
customers would leave the queue. In Kumar and Swaminathan (2003), the Bass model is extended 
further with capacity constraints for finding separate sales and production plans. As demand cannot 
always be backlogged without loss of sales, finding a sales plan is not trivial. In an extensive 
numerical analysis, the authors make a comparison between a myopic policy looking to sell as 
much as possible at all times versus a build-up policy, where inventory is built up before demand is 
served. No unambiguous result is found. Several insights on optimality of the build-up policy and 
the possibility of a delayed roll-out are obtained. By introducing a convex production cost curve, 
the authors describe, how the model can also be used for finding appropriate capacity levels. Risk 
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packaged inventories are not considered i.e. there is no risk related to build up inventory. Having a 
similar research objective, Ho et al. (2002) also extend the Bass model with supply constraints in a 
very similar approach. In contrast to Kumar and Swaminathan (2003), they claim that it is always 
optimal to sell as much as possible given that production is using all capacity. The authors also 
point out, that the news vendor problem cannot be used as it does not account for non-stationary 
demand and continue to deduce several properties for optimal operating conditions, life cycle profit, 
optimal TTM and capacity level. To address supply chain design for new products, Amini and Li 
(2011) propose a model extending from the Bass model, which directly incorporates supply chain 
configuration decisions and safety stock placement. As in Kumar and Swaminathan (2003) the 
model is compared to both a myopic and a build-up policy. The scope of these models is however 
highly aggregate. In addition, they also do not consider uncertainty. Hence these papers do not aim 
at and are not suited for supporting launch preparation decisions. A related stream of research 
focusing on market entry decisions should also be mentioned, lately represented by Özer and Uncu 
(2013). Here lost sales of delaying market entry are traded-off against extra development time for 
electronic components. In the pharmaceutical industry, this problem does not exist, because the 
product development has been completed and the product tested.  
Supply chain issues in the pharmaceutical industry are reviewed comprehensively in Shah 
(2004). The new product introduction process was identified as the largest industry challenge. The 
following key planning areas were identified: pipeline planning, capacity planning and production 
planning. The scope of these planning challenges can be seen in Figure 3.2. Recently, Laínez et al. 
(2012) made an updated review of the latest developments in planning for the pharmaceutical 
industry. Apart from a thorough review of capacity and pipeline planning, they also cover supply 
chain management issues. The topics most related to our work are drug supply for the clinical trials 
and supply network planning in general. Market launch planning is not directly addressed. 
 Some contributions directly address the introduction of a new product in the pharmaceutical 
industry. Rossetti et al. (2011) present an empirical study of trends in pharmaceutical supply chains. 
Though they cover increasing pressure on the reimbursement levels and negotiation process, they 
mostly focus on the link between manufacturers and wholesalers. Gjerdrum et al. (2001) look at 
new product introduction in general and use the pharmaceutical industry as an example. The authors 
develop a simulation model of a pharmaceutical supply chain which can be used for assessing the 
consequences of introducing a new product. Sundaramoorthy and Karimi (2004) address supply 
chain management during new product introduction for the pharmaceutical industry. Here, a 
campaign planning model for API production in a multipurpose batch plant is developed to test how 
the introduction of a new product affects the existing products. The model considers deterministic 
demand, but the authors argue that their model can address demand uncertainty via reactive 
scheduling. Reactive planning however is difficult to implement in the pharmaceutical industry due 
to the rigidity of the production plans for campaign production. Since the described uncertainties 
can suddenly materialize during market launch, it seems doubtful whether reactive scheduling is a 
sufficient methodology to address these uncertainties. Instead, solutions that account for the 
uncertainties up front are needed. Furthermore, a more aggregated view of the whole supply chain 
is needed due to considerable lead times.  
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This paper is to the best of our knowledge the first to develop a methodology for planning 
operations up to market launch, in particular for the pharmaceutical industry. It covers the gap 
between the approval of a new pharmaceutical drug and the launch of the product. We focus our 
attention on providing decision support for the launch preparation decisions in the face of the 
uncertainties from the authorization process. 
 
3.3. Problem definition and modeling approach 
3.3.1. Scope, assumptions and variables 
The production of API or primary production is followed by the production of the final packaged 
product or secondary production, which has a considerably shorter planning horizon. The key 
processes in secondary production are the formulation of the API (e.g. into pill form), packaging of 
the drug into blisters and then final packaging into boxes with leaflets and labels (cf. Figure 3.3). 
The formulation of the bulk drug is the same for all markets. In the blistering stage, products are 
market specific as the blisters contain some information related to the final market. Unlike the 
volumes produced in the packaging stage, they will not be affected by a forced label change as no 
information is put on the blisters which might be subject to last minute changes. Due to different 
languages and texts on the PPM, a packaged drug can only be sold on one market. As it is by law 
forbidden to repackage or transship the drug, a rejection of the PPM makes any finished product 
inventory obsolete. Procurement of leaflets and labels (i.e. PPM) also has to be considered. Due to 
the setups involved in the printing process, rush and small orders of PPM are infeasible or very 
expensive. Today’s supply chains frequently also involve contract manufacturers in secondary 
production with whom framework contracts need to be negotiated and capacities reserved. The 
resulting contractual agreements with the PPM supplier and CM lead to capacity restrictions, which 
have to be considered in launch preparation planning.  
The scope of our model covers production and inventory of API, CM, formulation, blistering, 
PPM supply and packaging of the final product (cf. Figure 3.3). To support the launch preparation 
decisions, only aggregate production and inventory volumes are required. In contrast, the detailed 
scheduling of jobs is not considered. The news vendor model is not suitable for a number of 
reasons. The demand is non-stationary (cf. (Ho et al., 2002)). We consider additional uncertainties 
and a full supply network. We require complete demand fulfillment after market launch but allow 
for a variation in the timing of market launches. Hence, we formulate a MILP model based on the 
following assumptions: 
 In order to capture TTM, lost revenue due to delayed market launch is considered. Lost market 
share due to delay is not modeled. 
 After market launch, all demand must be fulfilled as patients must have access to their 
medication. 
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 The outcomes of the authorization processes for different markets are independent due to the 
different institutions involved in the authorization process in the different markets. This holds 
for both duration of the process and label changes. Reimbursement levels are somewhat 
dependent, but we capture this uncertainty only as one of many factors influencing demand 
uncertainty. Demand uncertainty is independent as each regulatory body has its own approach to 
the cost-benefit analysis. 
 Due to the short time horizon considered, shelf life, which is normally around two years, the 
discount rate and other financial constraints are not considered.  
 
 
Figure 3.3: Supply chain considered (see variable definition below). 
 
We consider a market launch of a new product in a number of markets m M  in time periods 
t T . Given the lead times involved and the variations in the length of the authorization process, 
the model therefore covers a time horizon of 3-9 months divided into weeks.  
The uncertainty due to the demand uncertainty and the authorization risks is handled through a 
two-stage stochastic modeling approach. In a two-stage stochastic model, variables are divided into 
two categories (Birge and Louveaux, 2011). First stage variables (also called the design variables) 
are used for making ‘here-and-now’ decisions. Second stage variables (or the recourse variables) 
are used for making decisions after the uncertainty has materialized, i.e. are used for making ‘wait-
and-see’ decisions. For our problem, no probability distribution can be found as no historic sales 
information is available for new products. However, a set of scenarios s S  can normally be 
generated by experts, which enables the use of the deterministic equivalent of the two-stage 
stochastic programming formulation or simply scenario-based optimization or recourse 
programming. The ‘here-and-now’ decisions are modeled as scenario independent variables. 
Central are API and CM production and the label procurement variables as these decisions must be 
made well ahead due to the involvement of external parties (CM and PPM supplier) and due to the 
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lengthy and inflexible API production. Formulation and blister volumes are also first stage 
variables, since they are needed as input for secondary production planning. Furthermore, a master 
production schedule for the packaging capacity must be made to prepare the packaging facility for 
the coming launch. By reserving capacity, demand fulfillment for all scenarios is ensured. The 
scenario dependent ‘wait-and-see’ variables are all remaining variables including exact launch date, 
packaging and inventory variables. Since packaging and distribution are relatively simple processes, 
they are considered scenario dependent as they can be changed with short notice. An overview of 
first and second stage variables can be found below.  
 
Design or ‘here-and-now’ variables  Recourse or ‘wait-and-see’ variables 
,m t  = 1, if PPM is ordered for 
market m in period t; 0, 
otherwise. 
 
, ,m t s  = 1, if a launch is conducted in 
market m in period t in scenario 
s; 0, otherwise. 
,
l
m t  
volume of PPM (or labels) 
ordered for market m in period 
t. 
 
, ,m t s  product volume required for 
market m in period t for 
scenario s. 
,
b
m t  
volume of blisters packaged 
for market m in period t. 
 
, ,
p
m t s  
volume of packaged products 
for market m in period t in 
scenario s. 
, ,a f cmt t t  
 
volume produced of API, 
formulation at the company 
site and at the CM in period t, 
respectively. 
 
, , , , , ,, ,m t s m t s
p b l
s m t  
 
inventory level of packed 
products, blisters and labels 
respectively for market m in 
period t and scenario s. 
,t t
a f   inventory level of API and 
formulation in period t, 
respectively. 
 , , , ,,m t s
l
s m t
p   volume of scrapped packaged 
products and PPM caused by a 
forced label change for market 
m during period t and scenario 
s, respectively. 
,
p
m t  packaging capacity reserved 
for market m in period t. 
 ,m s  net cost of scenario s in market 
m.   
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3.3.2. Scenario modeling  
Even through there is a strong requirement for modeling approaches which consider more than one 
type of uncertainty in solving practical problems, there is only a limited number of such 
contributions (Mula et al., 2006, Barbosa-Póvoa, 2012). We model the three key uncertainties 
described in section 1 with the scenario structure shown in Table 3.2. When the authorization is 
awarded, the authorities also reveal if a change of the packaging material is required. If a change is 
required, then the launch decision has to be adjusted. Simultaneous with the authorization, the 
reimbursement level is also set, which impacts the sales price and demand. Also, the requirement to 
change the label has an influence on the demand as drugs may have to be scrapped and re-produced. 
It is assumed, that all uncertainties are known as soon as the authorization is given.  
 
Table 3.2: The possible scenarios for launching the new product in a single market. 
Scenario 
Authorization 
granted 
Label 
change 
required 
Demand 
1 Slow Yes Optimistic 
2   Realistic 
3   Pessimistic 
4  No Optimistic 
5   Realistic 
6   Pessimistic 
7 On-time Yes Optimistic 
8   Realistic 
9   Pessimistic 
10  No Optimistic 
11   Realistic 
12   Pessimistic 
13 Early Yes Optimistic 
14   Realistic 
15   Pessimistic 
16  No Optimistic 
17   Realistic 
18   Pessimistic 
 
As As can be seen in Table 3.2, there are 18 different scenarios s S  of the reimbursement 
negotiations for each market. Looking at all the markets, one such scenario will occur for each 
market. As all combinations are possible, the number of scenarios in the full combinatorial 
expansion set ˆs S  grows exponentially with the number of markets; 
| |ˆ | |MS S . A full 
combinatorial expansion of the 18 scenarios for each market from Table 3.2 for e.g. 5 markets 
would lead to 18
5
 ≈ 1,890 million scenarios; a number which is computationally intractable. This is 
a well-described problem with two-stage stochastic programming, which the modeling approach 
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should account for (Sodhi and Tang, 2009). We use the problem structure with divergent product 
flows to separate all decisions for the different markets. By using both the simple scenario s S  
and the market index m M  for all scenario dependent variables, decisions for each market are 
taken independently of other markets. The number of variables in our approach is reduced from 
| |ˆ| | | | | |MM S M S    to only | | | |M S  per time period for every type of variable. For example, the 
number of packaging variables for the full combinatorial expansion , ,
p
m t s  is thus reduced from 
9,450 million (= 1,890 million x 5 markets) variables per time period to , ,
p
m t s , with only 90 (18 x 5 
markets) variables per time period in our modeling approach, if 5 markets are considered. For 
scenario dependent constraints, a similar reduction in numbers results.  
 
 
Figure 3.4: An example of the reduction of flows for the simple case of 2 markets and 3 scenari-
os (|S| = 3). 
 
The divergent flow in the supply chain (cf. Figure 3.4) is modeled as follows. In the formulation 
stage, the product is identical for all markets. Due to the different commercial names, the drug 
becomes market specific in the blistering stage with the inventory balance decoupling the flow: 
PackagingBlisteringFormulation 
Inv
Blister 
Inv
Full 
Combinatorial 
Expansion
Scenario 
Decomposition
Finished Inv
Number of flows 
per time period
|M|*|S|
|M|
 
= 2x3
2
 
=18
|M|x|S|
=2x3 
=6
|T| |T|x|M|
|T|x|M|x|S|
or
|T|x|M|x|Ŝ|
Variables
# of variables
, ,
p
m t s,
b
m t
f
t , ,
b
m t s , ,
p
m t s
|T|x|M|x|S|
or
|T|x|M|x|Ŝ|
|T|x|M|x|S|
or
|T|x|M|x|Ŝ|
Formulation 
inventory 
balance 
Blister 
inventory 
balance 
 
Market A
 
Market A
 
Market B
 
Market B
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1 ,
f f f cm b
t LTF tt t m t
m
M
M
LTC t    

     . The coupling between the scenario independent and the 
scenario dependent variables is made in the blistering inventory balance:
,, , , 1, , , , ,
b b b p
m t LTBm t s m t s m t s m t s       . The incoming blister volume is scenario independent, but 
packaging volumes dependent on the scenarios consume different amounts of the inventory in 
different scenarios. The divergent structure expanding from one generic formulation volume to 
| | | |M S  flows of market and scenario dependent packaging volumes can also be seen in Figure 
3.4. In this small example in Figure 3.4 with only two markets and 3 scenarios (|S| = 3), the number 
of variables is reduced from 18 to 6 per time period.  
With the duration of the authorization process being uncertain, the scenario-dependent decision 
variables must be managed properly. When using the deterministic equivalent of a two-stage 
stochastic program, scenario-dependent variables before materialization of the uncertainty have to 
be identical as no more information is available. To address this challenge, two different approaches 
have been suggested. In Hahn and Kuhn (2012) it is addressed by defining variables within the time 
fence as scenario independent. However, if no well-defined time fence exists because the 
materialization of the uncertainty depends on an event which is not fixed in time, no appropriate 
variable definitions can be derived. Instead non-anticipatory constraints were developed in Goel and 
Grossmann (2006) for forcing decisions to be identical up to a time-varying point when some of the 
uncertainty has materialized. We use these non-anticipatory constraints to group decision variables 
together according to when authorization is granted in the respective scenario. Figure 3.5 shows 
how this is done. Here all decisions are identical prior to market authorization. After the 
authorization is given, different decisions can be taken. Up to earliest possible authorization, all 
packaging volumes and the packaged inventory have to be the same. For scenarios with early 
authorization (scenario 13-18), scenario dependent decisions can then be taken once the outcome of 
the authorization is known. Decisions for all other scenarios (scenario 1-12) still have to be 
identical. After on-time authorization, decisions in scenarios 7-12 can be made dependent on the 
outcome of the authorization process, while decisions in scenarios 1-6 have to be fixed until the 
delayed authorization has been given. 
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Figure 3.5: Illustration of how decisions are grouped together with non-anticipatory constraints. 
 
3.4. Model formulation 
 
Parameters  
, ,m t sA  
= 1, if a market authorization is given for market m in time period t in 
scenario s; 0, otherwise. 
, ,
,
,t
t
t t
t
CAPF CAPCM CAP
CCAPL APP
B
 
capacity for production of formulation, volume send to the CM, 
blisters, labels, packaged products in period t, respectively. 
 
,CFP CPL  cost of scrapping one unit of packaged product or one unit of labels, 
respectively. 
, ,m t sDEM  
demand for market m, t periods into the launch for scenario s.  
, , , ,HA HF HL HB HP  holding cost per period for API, formulation, PPM, blisters and 
packaged products, respectively. 
, ,m t sIPT  
= 1, if the inventory of market m during period t for scenario s has to 
be discarded due to a forced label change; 0, otherwise. 
, , , ,LTF LTCM LTB LTL
LTP  
lead time for formulation, the CM, blisters, labels and packaged 
products, respectively. 
OCP ordering costs for an order of PPM. 
,m sP  
probability that for market m scenario s occurs. 
time
, ,
, ,
 
and 
Identical m t s
p
p
m t s

, ,
, ,
 
and 
Identical m t s
p
p
m t s

, ,
, ,
 
and 
Identical m t s
p
p
m t s

S
ce
n
ar
io
s
,
, ,
,  
and 
Free m t
p
p
m t s
s

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, , , ,PA PF PCM PB PP  production cost of API, formulation, CM, blistering and packaging, 
respectively. 
,m sPR  
demand at peak revenue level for market m in demand scenario s. 
mREV  sales price for market m minus direct sales cost. 
mSFE  the needed product for filling the downstream supply chain in market 
m. 
U sufficiently large number. 
 
Objective function 
,
, , ,
,
( )
min (
) (1)
m s t t
m M s S t
a a f f
m s t t
cm
T
t
b l
m t m t m t
m M
PA PF
PCM PB PB OC
P HA
P
HF   
  




 
    
  
  
 

 
 
 
 
Subject to: 
Scenario-specific cost 
, , , , , , , , , , ,
, , ', , ',
'
, ,(
( ) , (2
)
)
l p b p
m s m t s m t s m t s m t s m t s
t T
m m s m t s m t s
t T t
l p
m t s
t
HL HP HB CFP CFL
REV
PP
PR A m M s S
     


 
      
 
       
 
    
 
 
 
Market launch 
, , 1 , (3)m t s
t T
m M s S

   
 
, ', , ,
'
, , (4)m t s m t s
t t
A m M t T s S

    
 
 
Product requirement 
, , , ', , ', , ,
'
, , (5)m m t s m t t s m t s m t s
t t
SFE DEM m M t T s S  

         
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Packaging 
, , , 1, , , , , ,,  , , (6)
p p p
m t
p
m LTt s m t s t sPm t s s m m M t T s S            
,, , , (7),
p
ms
p
tm t m sM St T      
, (8)
p
m t t
m M
CAPP t T

 
 
 
Non-anticipatory constraints 
, , ,, ,, ''
'
, , ' , 1,2,3 (9, )p p i nm t m t
i n
t t
m t s s s mU A s S s S nM t T 


       
 
, , '
'
, , , ' , , , ' , 1,2,3 (10, )
p p i n
m t m t
i n
t t
m t s s s m MU STA s S s nt 


       
 
, , '
'
, , , ' , , , ' , 1,2,3 (11, )
p p i n
m t m t
i n
t t
m t s s s m MU STA s S s nt 


       
 
, , '
'
, , , ' , , , ' , 1,2,3 (12, )
p p i n
m t m t
i n
t t
m t s s s m MU STA s S s nt 


       
 
 
Blistering 
, , , 1, , ,, , , (13)
b b b p
m t LTBm t s m t s m t s m M t T s S          
, (14)
m
t
b
M
m t CA t TPB

   
 
Formulation 
1 , (15)
f f f cm b
t LTF t LTt t m t
m M
CM t T    

      
 
(16)t t
f tCAPF T  
 
(17)m t
c
t CAPCM t T    
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API 
1 (18)
a a a f cm
t tt t t t T         
 
 
Label supply 
, , , 1, , , , , , , , (19)
l l l p l
m t m t LTLm t s m t s m t s s m M t T s S            
, , (20),
l
m t m t m M t TU       
, (21)
l
m t t
m
CAPL t T    
Scrap 
, , , 1, , , , , (22)m t s m t s m s
p p
tIPT m M t T s S        
 , , ,, 1, , , , , (23)l l lm t s m t m LTLs m t st IPT m M t T s S          
,, , ,
'
', , , (24)
l l
m t LTL
t
m t s m
LT t
t s
L t
IPT m M t T s S  
  
       
 
Domain restrictions  
 , , 0,1  , , (25)m t s m M t T s S       
 , 0,1  , (26)m t m M t T      
, , , , , , , , , , , , , ,  ,, , , , , , , (270 )m t s m t s m t s m t s m t s m t
p b l p p
s m s
l
t m M t T s S           
,, ,  ,, ,   0 (28)
p
m t m t
b l
m t m M t T        
, , , (20 9, )f cm af at t t t t t T        
, ,,  , (30)0m s m sUPM m M s S     
 
The objective of the model in Eq. (1) is to minimize the expected value of the total cost of the 
launch plan. The costs consist of the scenario dependent cost ,m s  
for each market, CM cost, PPM 
ordering and volume cost, blistering cost and production and holding costs of the API and 
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formulation. The scenario dependent cost (Eq. (2)) considers lost peak revenue which is calculated 
as the delay between authorization and launch multiplied with peak daily demand and the sales 
price from each market. Lost peak revenue is as such a measure for TTM represented in the 
objective function. Additionally, the cost of the scenario dependent scrap volumes, packaging and 
holding cost of blisters, labels and packaged volumes are considered. The drug can only be 
launched once per market (Eq. (3)). According to Eq. (4) launches cannot be conducted before 
authorization is granted. Eq. (5) finds the required amount of finished products needed. In this 
constraint, volumes for the filling of the downstream supply chain as well as the demand are 
considered. The upstream supply chain used to produce these finished products is modeled through 
constraints Eq. (6)-(21). Equations (6), (13), (15), (18) and (19) are inventory balances, equations 
(7), (8), (14), (16), (17) and (21) are capacity constraints. Eq. (7) determines the capacity reserved 
for each market to ensure that the required amount can be produced, ,
p
m t . The sum of these 
capacities over all markets needs to be smaller than the total packaging capacity (Eq. (8)). Eq. (9), 
(10), (11) and (12) are non-anticipatory constraints, which force decision variables on packaging 
volumes and finished product inventory before authorization to be identical for all scenarios to 
reflect that information about the future development is not available at this time (cf. the discussion 
in the previous section). In Eq. (20) the variable 
,m t , is set to 1 when PPM is ordered. This binary 
decision variable is required to capture the cost structure of for PPM. All PPM and risk packaged 
products on stock have to be scrapped, if a forced label change is required (Eq. (22)-(24)). Note 
that, through Eq. (24) all inbound PPM volumes also have to be scrapped. All remaining 
constraints, Eq. (25)-(30), are domain restrictions.  
  
3.5. Case study 
The key characteristics of typical pharmaceutical companies have been used to test the performance 
of the model in a series of numerical tests. A set of data has been created based on the information 
obtained in interviews with managers from 9 different pharmaceutical companies.  
The supply chain shown in Figure 3.3 is considered with all the illustrated elements and five 
different markets. The time horizon is set to 50 weeks. All costs are based on the production cost of 
the API being set to 1.0 monetary units. PPM cost is e.g. usually around 10 % of API cost and 
hence, PL is set to 0.1. The remaining costs in Table 3.3 have been created in similar fashion. The 
ordering cost of new PPM used to approximate the volume discount, is set to 25. The scrap costs 
represent the cost related to getting rid of the waste which often requires special treatment. Holding 
costs are set to 0.4 % per week of the product value at the respective stage in the supply chain.  
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Table 3.3: Cost parameters. 
Cost of Scraped 
Products 
PPM Ordering 
Cost 
Production Costs 
CFP CFL OCP PA PF PCM PB PL PP 
0.1 0.01 25 1.0 0.1 0.2 0.1 0.1 0.15 
 
The definition of the scenarios and market data depends on company, new drug type etc. To 
account for this variation, a number of problem instances have been created. Data intervals for 
individual markets from different European regions have been created by scaling data from Danzon 
et al. (2005). European markets are particularly interesting as they share the approval process (via 
EMA) but have separate authorization processes. The key data for the markets is given in Table 3.4. 
From these intervals, combinations of values were randomly drawn to give 25 different market data 
samples. Revenues 10 times higher than production cost are not unusual in the pharmaceutical 
industry. 
For the scenarios, two sets with different probabilities for a nominal negotiation length (which is 
usually given by the authorities), 2 weeks faster negotiation or a 2 weeks delay were considered. 
Hence the probability sets (early, nominal and delayed) are given by {20%; 40%; 40%} and {10%; 
30%; 60%}. The best and worst case demand scenarios are either ± 40 % or ± 60 % of the realistic 
demand level with worst, realistic and best case scenario demand occurring with a probability of 25 
%, 50 % and 25 %, respectively. The full combination of the authorization probabilities (2), the 
demand variation (2) and the market data samples (25) lead to 100 different instances in total. 
Maximum capacities and lead times can be found in Table 3.5. Capacities for PPM and CM are 
kept constant over time. For the remaining stages, capacity is increased from 0 to full capacity over 
the first 26 weeks (half a year). This curve can be seen as a linear approximation of the ramp-up 
process. Due to investment considerations, formulation capacity is set to the lowest total demand 
and CM will be used for the remaining volume, while inexpensive packaging and blistering 
capacity is set to the highest possible demand. Demand is described by an s-shaped market 
penetration curve (cf. (Cook, 2006)), which takes 25 weeks to achieve full market penetration and 
reaches 50 % peak demand after 14 weeks. The supply chain filling effect for new markets, SFEm, 
is set equal to the accumulated demand of the first 14 weeks.  
In Figure 3.6 the aggregated expected demand with on-time authorization and realistic case 
demand for all markets and the increase of packaging capacity can be seen for sample 15. The 
supply chain filling effect can obviously not be covered by just-in-time production. This effect is 
even more pronounced for higher demand scenarios and earlier market authorizations.  
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Table 3.4: Market data. 
Markets Sales price 
Expected peak 
demand level 
Risk of a forced Markets 
A [9;13] [800;1,000] [10;20] [10;15] 
B [2;4] [200;500] [5;10] [20;25] 
C [6;8] [1,000;1,500] [5;15] [15;20] 
D [9;13] [100;400] [15;25] [10;15] 
E [8;10] [400;600] [10;20] [8;12] 
 
 
Table 3.5: Capacities and lead times. 
Stage 
Maximum capacity Lead time 
Notation Value Notation Value 
Packaging CAPP 4,000 LTP 1 
Blistering CAPB 4,000 LTB 0 
Formulation CAPF 2,500 LTF 1 
PPM CAPL 4,000 LTL 3 
CM CAPCM 4,000 LTCM 2 
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Figure 3.6: Example of increase in packaging capacity and aggregated expected demand for on-
time authorization and best case demand for all markets from sample 15. 
 
3.6. Numerical analysis 
3.6.1. Baseline case 
The model was implemented in OPL Studio 6.0. Each problem instance has 2,280 binary, 15,775 
continuous variables and 123,391 constraints. All 100 instances were solved to optimality on a Dell 
Precision M65 with an Intel Core 2 T7200 2.00GHz processor and 2 GB RAM with 936 seconds of 
calculation time per instance on average.  
An example of the three central launch preparation decisions can be seen for sample 15 in Figure 
3.7. API supply volumes vary initially as the first inventory is build up. After period 15, the limited 
capacity of the supply chain can be seen, and CM volumes are used from period 36. 36 different 
PPM orders are made. Due to the ordering cost few orders with less than maximum volume are 
seen. The drop in all volumes in the last periods is due to end-of-horizon effect. 
Considering all 100 samples, the split between the different average costs in Table 3.6 shows the 
dominance of the production cost, but also shows the size of the lost peak revenue, which is 
comparatively small, indicating that in the optimal solution high priority is given to a short TTM. 
126 units of finished product and 10,871 units of PPM are expected to be scrapped. The large 
difference is due to the difference in cost and lead time of PPM compared to finished products. The 
CM produces 18 % of all the formulated volume. 
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Figure 3.7: The three central launch preparation decisions for sample 15. 
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Table 3.6: The average expected cost for all 100 samples of the baseline case. 
Cost type Cost % of total cost 
Exp. lost peak sales 16,214 9.32% 
Exp. production cost 148,876 85.59% 
Exp. scrap cost 121 0.07% 
Exp. holding cost 3,802 2.19% 
PPM ordering cost 1,065 0.61% 
CM cost 3,859 2.22% 
Total cost 173,938 - 
 
Table 3.7: Average expected delay and risk packaging percentage over all 100 samples for the 
baseline case. 
Market Revenue 
Expected launch 
delay for market 
[weeks] 
Expected 
peak demand 
level 
Percentage of supply chain filling 
covered by risk packaged inventory 
for market [%] 
A [9;13] 0.29 [800;1,000] 15 % 
B [2;4] 2.00 [200;500] 0 % 
C [6;8] 0.51 [1,000;1,500] 27 % 
D [9;13] 0.33 [100;400] 11 % 
E [8;10] 0.35 [400;600] 5 % 
 
The best measure of TTM for our problem is the expected delay of market launch. Table 3.7  
shows the expected delay and the share of risk packaging for each market. As packaging for smaller 
markets can be done in the week of the market launch, risk packaging is mostly required for larger 
markets, for which the capacity is insufficient to produce the supply chain filling volume just-in-
time as can e.g. be seen in Figure 3.6. The smaller markets B, D and E correspondingly require 
lower levels of risk packaging. The expected delays instead follow the sales price for the markets. 
Especially the less profitable market B and C are postponed. This corresponds to statements from 
managers who do not hesitate to down prioritize lower valued markets.  
 
3.6.2. Impact of supply chain structure and operations policies  
To gain managerial insight into the management of product launches in the pharmaceutical industry, 
further numerical experiments have been carried out. These include extensive tests of (a) different 
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supply chain configurations and (b) operations policies such as risk packaging and overstocking 
prevalent in the industry.  
The overall results of the numerical tests can be seen in Table 3.8, in which the key measures, 
expected cost, shipped volume, API, PPM and scrap volumes, have been indexed against the 
baseline case. For each market, the expected delay or TTM and risk packaging level i.e. the 
percentage of the supply chain filling volume on inventory immediately prior to launch is given in 
Table 3.9.  
 
Supply chain configurations 
In this section, we test attractive configurations of the supply chain different to the one presented in 
the case study. To find out how the PPM supplier influences the market launch, the two main PPM 
parameters used in our model are varied. We double the PPM lead time to see if reordering could 
delay the market launch. We also investigate whether doubling the ordering cost would lead to 
fewer PPM orders. Furthermore, we test a configuration without a contract manufacturer and 
expand formulation, blistering and packaging capacity with 20 % to find the value of additional 
capacity as a way of buffering against risk. Finally, we double all sales prices. This could represent 
products with a higher profit margin such as biologics. 
 
  
   
 
 
 
Table 3.8: Overall results indexed with the baseline case. 
Case Exp. cost Exp. shipped vol. API vol. PPM vol. 
Scrap vol. 
Ratio send to CM 
Packaged PPM 
Baseline case 100 100 100 100 100 100 100 
D
if
fe
re
n
t 
su
p
p
ly
 c
h
ai
n
 
co
n
fi
g
u
ra
ti
o
n
s 
Doubling PPM lead time 
(3 weeks → 6 weeks) 
101 100 99 100 96 111 98 
Doubling ordering cost 
(25 → 50) 
101 100 100 100 99 106 99 
No contract manufacturer 105 95 87 88 78 65 0 
20 % more capacity 99 100 101 101 51 88 61 
Double all sales prices 106 102 108 108 110 157 121 
O
p
er
at
io
n
s 
p
o
li
ci
es
 
Strictly enforced risk packaging* 101 100 101 101 569 134 93 
Strictly prohibited risk packaging 101 99 99 100 0 110 101 
Overstocking API 123 103 124 112 116 205 119 
API arriving in period 1 108 99 98 98 89 114 58 
*: 24 samples where infeasible and were hence not included in the results.  
  
 
 
Table 3.9: Solution structure of the numerical test. 
Case 
Expected launch delay for market 
[weeks] 
Percentage of Supply Chain Filling covered by risk packaged 
inventory for market [%] 
A B C D E A B C D E 
Baseline case 0.29 2.00 0.51 0.33 0.35 0.15 0.00 0.27 0.11 0.05 
D
if
fe
re
n
t 
su
p
p
ly
 c
h
ai
n
 
co
n
fi
g
u
ra
ti
o
n
s 
Doubling PPM lead time 
(3 weeks → 6 weeks) 
0.39 2.06 0.62 0.42 0.49 0.12 0.01 0.28 0.12 0.04 
Doubling ordering cost 
(25 → 50 ) 
0.30 2.08 0.55 0.35 0.35 0.13 0.01 0.26 0.12 0.05 
No contract manufacturer 0.59 4.27 1.43 0.78 1.31 0.10 0.00 0.20 0.12 0.06 
20 % more capacity 0.24 1.83 0.39 0.21 0.33 0.06 0.01 0.16 0.02 0.03 
Double all sales prices 0.17 0.59 0.23 0.21 0.12 0.17 0.05 0.27 0.12 0.04 
O
p
er
at
io
n
s 
p
o
li
ci
es
 Strictly enforced risk 
packaging* 
0.34 1.91 0.48 0.28 0.35 1.00 1.00 1.00 1.00 1.00 
Strictly prohibited risk 
packaging 
0.41 2.03 0.70 0.47 0.35 0.00 0.00 0.00 0.00 0.00 
Overstocking API 
estimate 
0.13 0.19 0.17 0.19 0.09 0.16 0.08 0.28 0.16 0.06 
API arriving in period 1 0.35 2.20 0.65 0.37 0.37 0.11 0.00 0.24 0.13 0.05 
*: 24 samples where infeasible and were hence not included in the results. 
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If the PPM lead time is doubled, the overall results are strongly affected, showing that PPM 
supplier lead time is critical for the market launch (twice the increase of doubling the ordering cost). 
The increase of the PPM ordering cost appears to have limited effect on the structure of the 
solutions. This shows that fast delivery of the PPM is far more important than discounts and 
ordering cost. Hence PPM suppliers should be selected based on lead time rather than price. 
Removing the contract manufacturer does have a large effect on the result as it limits the available 
formulated product ready at market launch. Without a contract manufacturer, insufficient quantities 
are produced and fewer products can be ready for launch in time. As a consequence the expected 
delay increases and the total cost goes up. Risk packaging is low as it is not possible to produce 
enough to risk package more. The test of increasing capacity proves that risk packaging is the result 
of low capacity. The increase also reduces both the total cost and TTM allowing managers to 
balance this effect against the investment in additional equipment. Doubling the sales prices 
increases the total cost due to the higher lost peak revenue. Reducing TTM becomes even more 
important. Accordingly, the expected delays are halved. This is made possible by increasing risk 
packaging, PPM ordering, scrap and CM use. These test show that even with different problem 
settings, our model still provide valuable decision support for launch preparation decisions.   
 
Operations policies 
Two different policies for risk packaging are tested against the baseline case. One is strictly 
enforced risk packaging, which prescribes that at least the supply chain filling volume has to be 
packaged and on inventory at the earliest authorization date. The other is strictly prohibited risk 
packaging in which no packaged product is allowed on inventory prior to market launch. Both strict 
risk packaging policies lead to higher cost than the baseline case. For enforced risk packaging, the 
increase is caused by additional scrapping. The available products lost this way also cause an 
additional delay for market A. For the prohibited risk packaging, the extra cost is caused by the 
increased TTM and the corresponding lost peak revenue. Our modeling approach offers a 1 % 
reduction of the total market launch and production cost in the first year by better balancing the cost 
and opportunities related to risk packaging.  
Due to (a) the lack of methods to accurately find the required API supply volume, (b) the 
stability of the API (i.e. no product expiration and hence scrap) and (c) the long lead time of the 
API, the required amount is often overestimated, according to managers. In general, the policy 
implemented by a number of our industry contacts forces overstocking the API inventory before 
market launch to cover all demand in all scenarios plus enough to account for incidents like forced 
label change. By introducing this volume in period 1 in our model, we were able to test the current 
practice against our model. The use of our model does lead to far better results as it lowers cost (-23 
%) by reducing scrap and obviously also lowers holding cost. Even if we force our model to also 
provide all API at the beginning of the planning horizon (API arriving in period 1), the saving still 
is 14 % of the total cost throughout the entire planning horizon.  
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However current practices lead to shorter expected delays and faster TTM. The difference in 
shorter expected delays comes from more risk packaging. This riskier behavior of overstocking API 
hence shows that managers are more likely to take on greater risk later, since they then have plenty 
of API anyway and might just as well use it instead of letting it sit in inventory. Large amounts of 
scrap result. When managers overstock API, they exclusively focus on reducing expected delays of 
the market launches i.e. shortening TTM, while losing the overall cost implications out of sight. 
This effect would be even more pronounced, if product perishability would be taken into account.  
 
3.7. Balancing TTM reduction with costs through robust optimization 
Using overstocking to reduce TTM is an indirect approach to lower TTM, which also leads to high 
holding cost and scrap cost as demonstrated in the previous section. In this section, we investigate 
how TTM can be reduced directly with lower unnecessary cost. With high sales prices, even short 
delays lead to considerable lost peak revenue. If a delay occurs in one scenario, its cost would be 
much higher than the expected cost over all scenarios. Hence, TTM can be reduced directly by 
reducing the variance of the cost for all scenarios.  
We use robust optimization to demonstrate this (cf. e.g. Mulvey et al. (1995)). Since we are only 
concerned with delayed markets, we only consider the positive deviation of the costs of each 
scenario above the expected cost i.e. first order upper partial moment or upper partial mean [UPM] 
(Nawrocki, 1999). First, we introduce a new variable, UPMm,s, which is a continuous variable 
representing the upper partial mean in market m of scenario s. The parameter λ is a weight for the 
upper partial mean, which is a measure for the risk aversion of the decision maker. We introduce 
the following changes to our model. 
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In Eq. (31), the objective function is expanded with the term for UPMm,t weighted with λ. 
UPMm,t is set in Eq. (32) as the positive difference between the value of all scenarios in a market 
and the expected solution for all scenarios. The value for λ depends on the risk aversion of the 
responsible manager, in that increasing risk aversion is reflected in increasing values of λ. Eq. (2) to 
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(30) remain the same. The effect has been tested and the results can be seen in Figure 3.8. Scrap, 
ordering and CM cost are small and fairly stable and have been omitted. TTM is reduced as can be 
seen in the shorter expected delays in Table 3.10, though the expected delay for each market is 
rather unstable. For λ = 2, TTM has been significantly reduced for only 3 % additional cost. The 
increase in cost in attributed main to production and holding cost and only to a lesser extend higher 
scrapping cost. It should be noted, that since robust optimization reduces the variance (UPM in our 
case), solutions with the same delay over all scenarios may occur. This effect is an obvious 
shortcoming of this risk management approach. As λ has no natural upper bound, each manager has 
to decide, how much he or she is willing to pay for a lower TTM. In our case for λ values between 0 
and 2, the Pareto relationship between lost peak revenue and the total cost is shown in Figure 3.9. 
The more risk of a market launch delay a manager is willing to take, the lower are the expected cost 
of the entire market launch. Conversely, if the manager is risk averse, a lower risk of a delay can be 
ensured by accepting a higher expected total cost. 
 
 
Figure 3.8: Results for different λ values. 
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Figure 3.9: The Pareto curve. 
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Table 3.10: Numerical test for varying values of Lambda. 
Lambda Exp. cost Exp. shipped vol. Scrap packaged vol. UPM Total risk packing 
Expected delay in weeks 
A B C D E 
λ = 0.0 100.00 100.00 100.00 100.00 100.00 0.29 2.00 0.51 0.33 0.35 
λ = 0.5 100.50 101.09 101.04 71.19 100.69 0.21 1.25 0.35 0.25 0.22 
λ = 1.0 101.63 101.73 104.50 52.45 103.35 0.76 0.16 0.57 0.03 0.07 
λ = 1.5 102.34 102.07 108.76 44.52 106.56 0.15 0.64 0.21 0.22 0.13 
λ = 2.0 102.97 102.28 108.95 39.70 106.99 0.15 0.47 0.18 0.19 0.13 
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3.8. Conclusion 
Treating the topic of market launch planning of new pharmaceutical drugs, we identified three key 
risks or uncertainties; the uncertain duration of the authorization process, the risk of a forced label 
change and uncertain reimbursement levels. We developed a two-stage stochastic MILP model for 
addressing market launch planning. The key launch preparation decisions are the required API, 
PPM, CM, formulation and blister volumes and reservation of packaging capacity, which have to be 
planned up front (or here-and-now). All possible launch dates are found on a wait-and-see basis as 
they depend on the outcome of the authorization process. Additional wait-and-see decisions 
included packaging volumes and blistering inventories. As the uncertainties materialize at 
undetermined points in time due to the uncertain authorization date, non-anticipatory constraints are 
used for forcing decisions prior to the authorization to be identical. The model was reduced in size 
by using the problem structure to reduce the number of scenarios. A case study was created which 
reflects the reality of the industry and an extensive numerical test was carried out. Risk management 
was used as a more systematic approach to deal with TTM cost and opportunities. 
In the numerical test it was possible to demonstrate the applicability of our modeling approach. 
In summary, our numerical analysis has led to the following managerial insights: 
 Risk packaging is a consequence of limited capacity. In order to reduce TTM focus should be 
given to the larger markets as their size does not allow for a just-in-time production of the 
required volumes.  
 Unavoidable market launch delays should be pushed to less profitable markets.  
 Our modeling approach performs better than a strict risk packaging policy due to a better trade-
off between cost and opportunities involved in reducing TTM. 
 PPM suppliers should be chosen based on lead time performance rather than cost.  
 There is a 14 % cost reduction to be gained from applying our model instead of using an 
overstocking rule for estimating the API supply volume as observed in the industry today. 
 Overstocking API before market launch leads to more risk affine decision making (larger risk 
packaging volumes) which result in higher scrapping cost. 
 Using robust optimization with the upper partial moment, we demonstrated that the lowering of 
the TTM goes along with only a modest increase in cost – if properly managed. 
 
We also showed that our model in principle also is applicable for new products such as the fast 
growing group of biologics which have a higher sales price. However, the implications of the more 
demanding and costly API production process deserve further investigation. Our model does not 
suit generic manufacturers in its current form, as the forced demand fulfillment assumption is too 
strict and the problems with the reimbursement negotiations are much smaller. 
There are several ways to expand the work presented in this paper. Capacity was here modeled in 
a standard way, but was shown to be the key for effective market launch. The main limitations that 
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go along with such a modeling approach come from a) the potential competition of the new product 
with other products for the production resources and b) from the limited initial skills of workers, 
which increase during ramp up as experience is gained. As identified in the literature review, 
contributions have already addressed the impact of introducing a new product into a multi-product 
pharmaceutical supply chain. Several studies have also covered ramp up of production. However, 
ramp up in multi-stage multi-site production such as often present in secondary pharmaceutical 
production seems to be largely untouched.  
We assumed that the uncertainties are all independent. For the uncertain reimbursement level 
independence between markets is not completely accurate as reference pricing is used often used. 
Incorporating such interdependencies in our already complex structure of uncertainties is 
challenging, especially considering that the use and influence of reference prices is not transparent.  
Though we have addressed inventory levels, we have not considered safety stock levels. The 
usual safety stock calculations neither consider ramp up of capacity nor the risks described here, 
which could be worth further investigations.  
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Chapter 4: Modeling ramp up for secondary pharmaceutical production 
 
This chapter is based on an article submitted as: 
Hansen, K. R. N., Grunow, M. (2013). Modelling ramp up in the context of secondary 
pharmaceutical production, submitted for International Journal of Production Research  
 
Abstract 
Ramp up is the term used to describe the increase in production capacity over time as experience 
with producing a new product is gained. Due to time-consuming demand diffusion, full utilization 
of production is not always the best production policy during ramp up. However, current ramp-up 
models all assume full utilization, which leads to an overestimation of the available production 
output during ramp-up. We therefore develop a methodology for capturing ramp up of effective 
capacity as a function of the cumulative production volume, which better reflects the experience 
gained with producing the new product. We demonstrate our more accurate and computationally 
effective method for the case of secondary pharmaceutical production. We develop a capacity 
planning model for a new pharmaceutical drug, which determines the number of new production 
lines and the build-up of inventory such that product availability at market launch is ensured. We 
apply our MILP model to a real industry case study using three empirically observed ramp-up 
functions to demonstrate its value as decision support tool. We also demonstrate the superiority of 
our ramp-up modelling approach over traditional time-dependent ramp-up functions and derive 
several insights into ramp up management. 
 
4.1. Introduction 
4.1.1. Ramp up and experience 
Product life cycles are shortening and new products success is essential to companies continued 
profitability. Several studies have investigated which factors contribute to the success of new 
products (e.g. (Cooper and Kleinschmidt, 1995)), but little research has looked into how to manage 
product launch from an operations perspective (Bowersox et al., 1999). Achieving new product 
success requires that sufficient volume of the product can be produced, which is especially 
important in the early life of a new product, when it can typically be sold at a premium price such as 
seen in the electronics (Terwiesch and Bohn, 2001) and the pharmaceutical industry (Hansen and 
Grunow, 2010). Hence well-managed supply chain operations for product launch are important, but 
have been limited to focus on capabilities and forecasts in the literature (van Hoek and Chapman, 
2006). The availability of the product in this phase is however often limited by the slow increase in 
production volume referred to as ramp up. Ramp up of production is becoming increasingly 
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important in industries such as automotive (Schuh et al., 2005) and electronics (Terwiesch and 
Bohn, 2001). Given the premium sales prices of new products, poor ramp-up performance and 
failing to meet demand has a very profound impact on a company’s bottom line. When Apple 
introduced its iPhone 5 in late 2012, it was sold out in the opening weekend. Despite the apparent 
success, investors send the stock down 1.4 % as Apple missed out on selling an approximate 1 
million units extra (Owens, 2012). 
The ramp-up phase or simply production ramp up starts when a new product is introduced into 
production and finishes when the target capacity is reached. During this phase, managers and 
workers are gaining experience with producing the new product allowing them to extend the 
production capabilities. We refer to these production capabilities as effective capacity and the 
increase of effective capacity over time as production ramp up (Figure 4.1). The curve showing the 
increase in effective capacity is called the ramp-up curve. The effective capacity does however not 
have to be used. The actual production volume can be smaller than the effective capacity, leading to 
a capacity utilization smaller than one. These terms are illustrated in Figure 4.1. For the automotive 
industry, large demand leads to full utilization during ramp up (Schuh et al., 2005), but this does not 
hold for all industries. 
 
 
Figure 4.1: Illustration of the used terms in production ramp up. 
 
Traditional models normally describe the increase in effective capacity over time. Such models 
however use the assumption that all the effective capacity is used i.e. that the utilization is always 1. 
This is only true if ample demand ensures everything can be sold (as is usually the case for example 
for new models in the automotive industry). For other industries, balancing supply and demand may 
result in a lower utilization at times. In this case, the full effective capacity found via traditional 
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models is misguiding, due to the shortfall in experience gained. The true experience gained is not 
captured and the measure of effective capacity is not accurate. A method in which the increase in 
effective capacity is captured as a function of cumulative production volume would instead provide 
a better expression for the true experience gained and hence be more accurate. The main focus of 
this paper is to develop exactly such a method. 
To elucidate this problem, we consider secondary pharmaceutical production, which comprises 
the production stages involved in turning the active pharmaceutical ingredient [API] into pills or 
putting it into more advanced drug delivery systems before finally packaging it. Here we consider a 
new pharmaceutical drug, which requires new dedicated production equipment. Secondary 
pharmaceutical production displays significant ramp-up effects when production of a new product is 
started as the manufacturing processes resemble regular discrete part production in other industries. 
This is especially true for more advanced drug delivery systems, which are made up of mechanical 
components requiring assembly. In addition to manual operations such as assembly and material 
handling, strict regulations on documenting safety and traceability lead to extensive compulsory 
quality assurance and documentation processes, which also have to be learned by the employees. 
The following section provides background information on the case of secondary pharmaceutical 
production. 
 
4.1.2. Ramp-up planning for secondary pharmaceutical production 
Regulatory authorities such as the Food and Drug Administration [FDA] or European Medicines 
Agency [EMA] impose strict requirements on the performance of investigational new drugs during 
the clinical trials. If successful, the product is said to have been approved. However, if unsuccessful, 
the project is discarded and the investment in R&D is lost. An approved drug will enjoy the 
protection of a patent, which may be highly profitable. For this reason, pharmaceutical 
manufacturers manage ramp-up processes with strong focus on decreasing Time-to-Market [TTM] 
to have the drug in the market under patent protection for as long as possible. However patents, 
which are normally filed early in the R&D process, have often lost most of their protection period 
when the drug is launched (Laínez et al., 2012). When patents expire, competing drugs from generic 
off-patent pharmaceutical manufacturers quickly enter the market, leading to strongly reduced profit 
margins. In addition, increasingly hard reimbursement negotiations have to be carried out with the 
healthcare authorities to gain final market authorization, because the authorities are focusing on 
keeping expenditures down. These negotiations about price and reimbursement levels are further 
reducing the exclusivity period in the market. To keep TTM as low as possible, product availability 
at market launch is paramount and production managers have to guarantee they can deliver the 
required volumes of finished product (Pisano and Rossi, 1994). This challenge managers to improve 
operations further, and necessitates new planning methodologies (Hansen and Grunow, 2010).  
With the construction of new factories and production lines lasting years, capacity planning for 
the API has to be made before the outcome of the clinical trials is known. New capacity is hence 
exposed to a considerable risk of a drug failing the clinical trials in which case the new product 
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would never reach production and the investment in capacity is lost. For capacity planning for the 
API, decisions on capacity expansion normally have to be made 4-5 years before launch as can be 
seen in Figure 4.2 (Papageorgiou et al., 2001, Gatica et al., 2003). The production of the API is 
referred to as primary production. In contrast, secondary production, consisting of bringing the API 
in a consumable form, is often simpler.  
 
 
Figure 4.2: Overview of the tasks during new product introduction in the pharmaceutical indus-
try. 
 
The construction of new production lines in secondary production takes only around 3 months. 
This allows pharmaceutical companies to make decisions on secondary production capacity once 
the (preliminary) results of the clinical trials are looking so promising, that companies are confident 
the new product will get approved. Failure to obtain an approval is at this stage not considered 
anymore. Capacity expansion of secondary pharmaceutical production takes place in a short and 
well defined time frame close to market launch with capacity planning decision having to be made 1 
to 1½ year before market launch as can be seen in Figure 4.2. This type of production displays 
significant ramp-up effects. Due to time-phased market launches and slow demand diffusion, 
production capacities are also frequently left unutilized. An effect further pronounced by the need to 
produce small volumes for process validation purposes long before market launch. 
During the market launch phase, demand varies significantly. At market launch, companies have 
to have large volumes of finished products ready for filling the downstream supply chain, so the 
drug will be available in hospitals and pharmacies when patients needs it. We refer to this as the 
supply chain filling volume. Some companies are able to send out filled trucks with the new product 
within an hour after they receive the final market authorization. To cover this demand, production 
has to be ramped up and inventory built up without overinvesting in capacity. After market launch, 
the sales of a new drug follow a typical demand diffusion process as the drug gets used by more and 
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more patients (Cook, 2006). For pharmaceutical drugs this process often takes up to a year as 
patients are extraordinary loyal to their old (and less efficient) medication. 
In order to sell products in a given market, the production of those products must first be 
validated by the authorities. Most authorities prescribe a set of guidelines referred to as Good 
Manufacturing Practices [GMP] for how pharmaceutical production equipment and utilities must be 
cleaned and handled to not put the patients at risk. To obtain a validation, the production of a 
minimum volume in a controlled and safe manner must be documented (FDA, 2011, EMA, 2012). 
Living up to these guidelines requires a significant investment in time and money to upgrade 
production and utilities and compiling the required documentation. It takes around six months for 
the authorities to finish reviewing the validation documents. A production site only has to be 
validated once, so the validation process does not have to be repeated for every production line. 
Though validation is required for selling the product, it is not required for producing it. This means 
that inventories can still be built up towards market launch before the authorities complete the 
validation process. The production process is normally validated as part of the approval application, 
but this is not strictly required.  
The task of building and installing production lines is carried out by engineering firms with 
specialized engineers and technicians. When several production lines have to be installed, the 
number of specialist teams limits the number of lines constructed simultaneously. These limited 
resources in the construction of the production lines have to be considered.  
Normally, the API is a stable compound, but when it is formulated, the drug starts to deteriorate. 
Though the actual shelf life is usually a couple of years, the effective shelf life available to the 
company is much smaller as a sufficient remaining shelf life is required, when the product is 
shipped out. 
The uncertain duration of the reimbursement negotiations with the authorities increases the 
uncertainty about the earliest possible launch date. Demand uncertainty is high, as forecasts for the 
new drug build on estimates rather than historical data and are influenced by the uncertainty about 
price and about the health claims the company is allowed to make about the new drug. Nonetheless, 
due to the high profit margins of the drug, capacity planning for secondary production is done 
purely based on the scenario with the highest demand and earliest launch date. Addressing demand 
variations should be done in the following preparations for market launch, where decisions on 
required API volume and supply of packaging material must be made (Hansen and Grunow, 2014). 
Secondary pharmaceutical production on dedicated lines is an excellent case in point of a 
production system for which capacity is not fully utilized during ramp-ups. As described above, 
demand diffusion for new products is slow, but at market launch, large quantities of the drug must 
be available to fill the downstream supply chain. As production must be ramped up to cover this, 
sufficient dedicated lines must be set up, but excess effective capacity is available after market 
launch. Full capacity utilization would lead to too high holding costs. In addition, due to limited 
shelf life, excess inventory would expire before reaching customers. Furthermore, production must 
be validated by the authorities well before market launch, leaving plenty of time until market launch 
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during which capacity utilization is low. These factors make it difficult to manage the ramp up as 
the experience cannot be described as a function of time. Instead it must be found as a function of 
the cumulative production volume.  
The focus of this paper is to show how to capture production ramp up via cumulative production 
volume and to exemplify this modelling approach for the case of secondary pharmaceutical 
production. For a new pharmaceutical drug we find the right number of new production lines to 
open and the time of these investments, that allows balancing supply and demand over the entire 
market launch phase are the key decisions. The underlying trade-off is that of balancing holding 
cost and fixed production cost of producing large volumes far ahead of market launch with the 
investment cost of having multiple production lines available to cover demand.  
 
4.1.3. Paper contributions and structure 
In this paper, we develop a new method for capturing production ramp up better by relating the 
increase in effective capacity to the experiences gained in production. We show this in a model for 
capacity planning of secondary pharmaceutical production, which is able to find which production 
lines to open when, such that enough of the new product can be produced and inventory build-up 
before and during market launch. We contribute to ramp-up literature by: 
 developing one of the first quantitative approaches to provide decision support in ramp up 
management, 
 conceiving a computational effective method for relating effective capacity to cumulative 
production volume to capture the actual experience gained in production of a new product 
thereby modelling ramp up more accurately,  
 demonstrating the value of our approach in the context of secondary pharmaceutical production, 
 deriving several managerial insights into ramp-up management in the context of the case study.  
 
In the next section we review of the scarce literature modelling ramp up and give an overview 
over capacity planning in the pharmaceutical industry. Thereafter follows a presentation of how we 
capture ramp up in section 3. The capacity planning model in which we use our method is presented 
in section 4. Section 5 contains the case study from the pharmaceutical industry in which the value 
of our way to model ramp up is presented. Concluding remarks and further research topics are 
presented in the final section. 
 
4.2. Literature Review 
The literature is inconsistent on how to define ramp up, but it generally refers to an increase in the 
effective capacity of the production over time starting from the first production until target capacity 
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has been reached (Ball et al., 2011). In Surbier et al. (2012), the literature on ramp up is classified 
according to keywords, industry and focus area. Challenges and research opportunities are outlined. 
The contributions reviewed are all empirical. The literature mainly treats the ramp up in the 
automotive and electronics industries and most literature focuses on how to organize the ramp up 
and to measure performance. In Clarke and Fujimoto (1991), the ramp up in the automotive 
industry is analysed and the strong link to the underlying learning process is clarified. Both Clarke 
and Fujimoto (1991) and Almgren (2000) find the ramp up of effective capacity in the automotive 
industry to follow an s-shaped curve over time. Risse (2003) shows the ramp up in the same 
industry to follow both an s-shaped and a power function. For the semi-conductor industry, Baud-
Lavigne et al. (2010) show with a simulation model, that the ramp up follows an exponential curve, 
which is supported by the model developed earlier by Weber (2004). To the best of our knowledge, 
there is no study which considers the ramp up of secondary pharmaceutical production or medical 
devices. 
Though the literature is full of empirical work on ramp-up management, only few contributions 
describe how to model ramp up in operations planning. Terwiesch and Bohn (2001) use the 
distinction between autonomous learning and learning by experiments introduced by Adler and 
Clark (1991). Learning through experiments creates a trade-off between how managers should use 
machine hours; either for regular production or for experiments which create extra capacity in 
subsequent time periods, but cost crucial capacity in the first periods after launch during which 
customers will pay a premium price. Matta et al. (2007) develop a closed expression to decide when 
and how many machines to ramp up using a Markov decision process. Their work is complemented 
by Niroomand et al. (2012), who focus on selecting either dedicated, flexible or reconfigurable 
manufacturing systems with different cost and ramp-up curves. Production ramp up is strongly 
linked to the underlying learning process where production workers gain proficiency with the 
process. Generally, learning is a vastly researched area. This has led to the development of several 
different learning functions, which all measure worker performance over time or cumulative 
production volume (Anzanello and Fogliatto, 2011). Ramp up and learning can however not be used 
interchangeably. While learning captures the increased proficiency gained by the individual worker 
in performing repetitive tasks (Biskup, 2008, Anzanello and Fogliatto, 2011), ramp up refers to an 
entire production system (Ball et al., 2011). Glock et al. (2012) consider dynamic planning and 
model ramp up in more detail. The authors use a given data set from an electronics manufacturer 
found in Badiru (1995) to find the ramp up and demand functions via regression. The ramp-up 
function is approximated with the constant time model from the learning literature. They develop a 
lot sizing model for finding the lengths of the production runs that match a steadily increasing 
demand, similar contributions to many other contributions which include learning effects in 
scheduling (cf. Biskup, 2008). Their approach to model production is not sufficient for considering 
a production network nor can it be used for finding the required capacity. Additionally, their model 
also only holds for a non-decreasing demand function, whereas we consider higher demand 
fluctuations from the supply chain filling effect and time-phased launches in different markets.  
The central tasks in planning for the pharmaceutical industry are first described by Shah (2004), 
who identifies the reduction of TTM as the key challenge for the whole industry. Six planning 
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domains are singled out of which the most important are pipeline planning, capacity planning and 
production planning. The work of Shah (2004) is followed by Laínez et al. (2012), who additionally 
introduce supply chain management, part of which is also to ensure the supply of the experimental 
drug for the test patients during clinical trials. Narayana (In press) reviews the entire literature on 
supply chain management for the pharmaceutical industry and illustrate the domains of literature. It 
concludes, that there is limited research covering the integration of supply chain management and 
new product introduction. 
Capacity investments in primary production are strongly related to the uncertainty in the 
development of a new drug. If the drug is abandoned, the investments both in R&D expenditures 
spent on product development as well as new production equipment are lost. Capacity planning for 
primary production is well described by Pisano and Rossi (1994) based on a case study from Eli 
Lily. Rotstein et al. (1999) developed a model which can both identify the appropriate number of 
production lines to invest in, while selecting profitable candidate products and finding annual 
production volumes. The authors extend their work in Papageorgiou et al. (2001) to cover the full 
supply chain and to reflect the business structure of large pharmaceutical companies. However, due 
to the extension of the model, uncertainty is not accounted for. Gatica et al. (2003) subsequently 
develop a better model for addressing uncertainty. Not just originating from the clinical trials, but 
also from demand. Gatica et al. (2003) and Papageorgiou et al. (2001) are unified in Levis and 
Papageorgiou (2004), who develop a multisite model that also considers uncertainty. Tsang et al. 
(2007a) present another capacity planning model which in Tsang et al. (2007b) is supplemented by 
to a vast series of risk management techniques. Chambers et al. (2009) present a stochastic dynamic 
optimization model for deciding on whether to invest in flexible or dedicated production equipment. 
Finally, Sundaramoorthy et al. (2012a) consider the capacity planning for continuous 
pharmaceutical production and model capacity and production rate expansions in increments. They 
focus on better capturing the uncertainty of products getting the approval and include some of the 
latest developments in pipeline planning into their model. In the companion paper (Sundaramoorthy 
et al., 2012b) they address solving industry-sized problems. 
While capturing the uncertainty of the approval, capacity planning for primary production does 
not fully capture the dynamics of the market launch phase. Due to the size of the time buckets in 
these long-horizon models, ramp-up of production is not captured. The scope of these models 
renders them inapplicable for determining the ramp up of secondary production. An approach 
dedicated for capacity planning of secondary production is therefore developed in this paper, which 
copes with large demand variations around market launch and significant ramp-up effects. 
 
4.3. Modelling ramp up depending on cumulative production volumes 
To better reflect the experience gained with the new production process in production, a method for 
linking the effective capacity to the cumulative production volume is needed. Our approach is 
inspired by the learning literature. We only consider learning-by-doing and neglect experiments as a 
source of effective capacity increase. With production not being interrupted for a long time, 
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forgetting can be ignored. We also do not consider the labour force or quality issues directly, but 
instead only focus on the relationship between experience and effective capacity. 
Three principal ramp-up curves are observed in other industries (mainly automotive and 
semiconductor); a power curve, an s-shaped curve and an exponential curve, which we will 
represent via three archetypical functions. The power curve observed by Risse (2003) can be 
expressed by the power function as: 
(1)y t   
Where y is the effective capacity, t is time, α and β are parameters. This function obviously does not 
converge towards the target capacity, but target capacity would still limit the effective capacity. 
Risse (2003) also offers an expression for the s-shaped curve, which he describes through two 
different power functions. Instead, we model the s-shape through a sigmoid function, which has the 
more general form: 
(2)
(1 )b t
a
y
c e 

   
For the sigmoid function, a = 1 represents the target capacity, while b and c are parameters that 
determine the slope of the curve.  
Glock et al. (2012) found that the time constant function from the learning literature best 
resembled the observed ramp up of effective capacity in the electronic industry. The function is here 
given as: 
/(1 ) (3)ts ny y y e
     
ys is the starting effective capacity, yn the effective capacity increase rate and φ determines the rate 
of increase. Examples of the three introduced functions are shown in Figure 4.3. Though we here 
use these archetypical functions, managers do in practice have some influence over how effective 
capacity is ramped-up as they can control e.g. emphasis on quality (Terwiesch and Bohn, 2001) and 
number of product variants launched (Schuh et al., 2005). 
The three selected functions can be rewritten to show effective capacity over cumulative 
production volume. First we see, that the cumulative production volume, x, can be expressed as the 
integral of the ramp-up function 
0
( )
t
x f d    as seen in Figure 4.4. In this expression, we can 
isolate t and insert it into our ramp-up function to get 1
0
( ( ) )
t
y f F x    . We demonstrate these steps 
for the three functions in Appendix A. The curves of the resulting functions can be seen in Figure 
4.5. All of these functions are concave, which enables piecewise linear approximation without the 
need for using binary variables in a MILP model. Hence the ramp up can be approximated as a 
series of linear capacity constraints.  
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Figure 4.3: Three archetypical ramp-up curves observed in the empirical literature. 
 
 
Figure 4.4: Illustration of the relation between time, effective capacity and cumulative 
production volume. 
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Figure 4.5: The three ramp-up curves showing effective capacity as a function of cumulative 
production volume. 
 
The slope of the linear curves is denoted CRr and the intersection with the y-axis is denoted CLr 
for curve r R . Having effective capacity as a piecewise linear function over cumulative 
production volume, the effective capacity in a single period is illustrated in Figure 4.6. Given that 
the production on site l’s line i in period t is defined as 
,
l
i t , capacity in the beginning of a period is 
given as 
, '
'
l
r i t r
t t
CR CL

  . During the production period, more experience is gained which should 
also be accounted for. It is clear to see, that this increase in effective capacity is on average 
, / 2
l
r i tCR   for the period. In this expression ,
l
i t  must however be replaced to avoid a circular 
reference in the capacity constraint. We approximate 
,
l
i t  with , '
'
l
r i t r
t t
CR CL

   and acknowledge 
that this approximation underestimates the actual effective capacity as 
, , '
'
l l
i t r i t r
t t
CR CL 

   . 
To the best of our knowledge, no empirical literature has looked into ramp up of secondary 
pharmaceutical production. With the wide range of different types of secondary production, the 
ramp-up curves would likely also vary depending primarily on the production process. The 
electronics industry, for which an exponential ramp-up curve is observed, is characterized by 
automated equipment that produces large numbers of each product. In comparison, the sigmoid and 
power functions are observed in the automotive industry, in which fewer units are produced and 
more manual labour per unit is required. If these are the determining factors, we expect the highly 
automated production of pills to exhibit an exponential shape ramp up just as seen in the electronics 
industry. The production of advanced drug delivery systems in contrast requires assembly and may 
therefore follow an s-shaped or a power curve as seen in the automotive industry. We consider this 
0 50 100 150
Power function Sigmoid function Time constant model
Production output
Cumulative production volume 
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relation probable as a connection between product complexity and ramp-up performance is 
established (Pufall et al., 2012).  
 
 
Figure 4.6: Illustration of the capacity in period t. 
 
4.4. Development of a mathematical planning model for secondary 
pharmaceutical production ramp up 
Pharmaceutical companies about to launch a new pharmaceutical drug have to have the product 
available at market launch to keep TTM down. To guarantee this, the right location and time for 
opening new dedicated secondary production lines must be determined. Here a model for providing 
decision support for this problem is described. As secondary production must be ramped up while 
having to leave production lines unutilized at times, effective capacity is modelled more accurately 
as described in the previous section.  
 
4.4.1. Model description 
A new product is introduced into different markets with different authorities m M . Since the new 
drug might be vital to patients, demand must always be fulfilled at this aggregation level. Figure 4.7 
illustrates the simplified supply chain considered. A company has a number of sites l L . Each site 
can house 
li I  new production lines, which can be opened in any given month t T . Not every 
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site has to have a production line. The lines are assumed identical and we do not consider the need 
for utilities, laboratories or any other supporting functions. The effective capacity of the new 
production lines can be limited by a set of linear capacity constraints related to the cumulative 
volume, r R . The supply of API is neglected as the inventory of API is regularly sufficient to 
feed secondary production. Contract manufacturers, which are common in the industry, have not 
been considered. Each site has an inventory of finished formulation, which can be sent to all 
markets the site is validated for. Packaging of the final product takes place after the formulation. As 
it is a fast and flexible process with usually ample capacity, it can be neglected. Due to the 
considered time horizon, the limited shelf life of a formulated drug has to be accounted for. With 
the planning horizon spanning several years, the value of money over time needs to be included 
through the use of a discounting factor. We consider no other financial constraints. 
 
 
Figure 4.7: Overview of the considered supply chain. 
 
4.4.2. Model formulation 
Indices 
 , 't t  time periods. 
 , 'l l  sites. 
 , 'i i  production lines. 
 
m  markets. 
 r  linear curves. 
 
 
Site 1
Site 2
Site 3
Inv
Inv
Inv
 EU
 US
 JP
API
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Sets 
 T  set of time periods. 
 L  set of potential production sites. 
 
lI  set of production lines in site l. 
 M  set of market. 
 R  set of linear curves. 
 
Parameters 
 
m
tA  = 1, if the final market authorization has been given and market launch for market 
m is possible in time period t; 0, otherwise. 
 CAP  capacity of every production line 
 rCL  initial effective capacity for linear curve r. 
 rCR  rate of effective capacity increase for linear curve r. 
 CT  construction time of a new production line. 
 
m
tD  demand in market m, t periods into the launch. 
 K  sufficiently large number. 
 MC  maximum number of production lines under construction, simultaneously. 
 mSFE  supply chain filling effect for market m. 
 SL  shelf life. 
 V  amount of product needed for validation. 
 VT  validation time. 
 D  discount rate. 
 
mGR  ross revenue for market m. 
 APIC  API cost. 
 
lF  construction cost of a production line in site l. 
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 H  holding cost for inventory per period per unit. 
 
,l mO  transport cost per unit from site l to market m. 
 lQ  running cost of a production line in site l.  
 
,l mVC  validation cost of enabling site l to produce and sell product for market m. 
 W  scrap cost per unit. 
 
Binary variables 
 
m
t  = 1, if the product is launched in market m in period t; 0, otherwise. 
 ,
l
i t  = 1, if in site l’s line i is starting production in period t; 0, otherwise. 
 
,m
t
l  = 1, if validation of site l is conducted for market m in period t; 0, otherwise. 
 
Continuous variables 
 
,l m
t  volume of product delivered from site l to market m in period t. 
 
l
t  volume of product on inventory at site l in period t. 
 ,
l
i t  volume of product produced in site l on line i in period t. 
 
l
t  volume of product scraped from site l during period t. 
 
Objective Function  
, , , , ,
, , ' ,
'
1
max ( ( ) ( )
(1 )
( )) (5)
m l m l m l m l m l m l l
t t t t tt
t l m l
l l l l l
i t CT i t i t
l i t t
GR O VC W H
d
F Q APIC
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  

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
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 
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Subject to: 
Sales Constraints 
,
' 1 '
'
, (6)m m m l mm t t t t t
t t l
SFE D m M t T   

       
 
1 (7)mt
t
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'
'
, (8)m mt t
t t
A m M t T

   
 
, ,
'
'
, , (9)l m l mt t
t t VT
K l L m M t T 
 
       
 
Material Balance
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1 ,  , (10)
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i t t t
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Manufacturing Constraints 
, , '
'
(1 ) ( )  , , , (11)
2
l lr
r r
t t
l
i t i t
CR
CR CL l L i I r R t T 

           
,  , , (12)
l l
i t CAP l L i t TI       
'
'
, ,  , , (13)
l l
t t
t
l
i
t
i K l IL i t T 

       
, 1  , (14)
l
i t
t
ll IL i      
, ', '
' '
, 1, (15)l li t i t
t t i i
l L i t T 
 
      
, ' 0 , (16)
l l
i t
t CT
l L i I

     
, '
'
(17)li t
t CT t t l i
MC t T
  
     
 
 
  Chapter 4 
77 
 
Shelf life Constraint 
,
, ' '
' '
, (18)l l l mt i t t
t t SL i t t m
l L t T  
  
        
 
Validation Constraint 
,
, '
'
, , (19)l l mi t t
t t i
V l L m M t T 

       
, 1 , (20)l mt
t
l L m M      
 
Bounds 
{0;1} , (21)mt m M t T      
, {0;1} , (22, )
l
t
l
i l L i t TI       
, {0;1} , , (23)l mt l L m M t T       
, 0 , , (24)l mt l L m M t T       
, 0 , (25)l lt t l L t T       
, 0 , , (26)
ll
i t l L i t TI       
 
In the objective function in Eq. (5), the net present value of the market launch phase is 
maximized. The first term represents the gross revenue from which transportation, validation, scrap, 
holding, construction, fixed production cost of each line and API cost are deducted, respectively. In 
Eq. (6), the volume of finished product shipped to each market in each period is determined and 
demand fulfilment is enforced. Note here the addition of the supply chain filling effect, which is 
only considered in the period with market launch. Market launches are governed by Eq. (7) and (8), 
in that market launches can only take place once and only after the authorization has been given. 
The option of delaying market launch ensures feasibility. Furthermore, the validation of the 
production process has to be completed, before the product can be shipped to the individual 
markets, which is ensured by Eq. (9). Eq. (10) is the inventory balance. In Eq. (11) the piecewise 
linear approximation of the ramp-up function based on the cumulative production volume is 
modelled as described above. Effective capacity is set lower than target capacity through Eq. (12). 
Eq. (13) ensures that production only takes place on open lines, and lines can only be opened once 
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(Eq. (14)). Eq. (15) orders the opening of production lines so the numerical lowest production lines 
are selected first to reduce computational degeneracy. Lines cannot be opened before they have 
been constructed (Eq. (16)) and construction is limited to only MC lines at a time to represent 
limited resources of the construction team (Eq. (17)). Shelf life is limited by assuming a FIFO stock 
keeping principle and not allowing the inventory level to be higher than cumulative difference 
between production and shipped volume for the length of the shelf life (Eq. (18)). Eq. (19) ensures 
that sufficient volume is produced for validation. Eq. (20) prescribe that a site is validated only once 
for each market. Eq. (21) through (26) define the variable domains.  
 
4.5. Case study 
For this case study, data from a real pharmaceutical company has been changed for confidentiality 
purposes. The supply chain in Figure 4.7 with three production sites and three markets EU, US and 
Japan is considered. The new product is launched (first) in these markets, due to their profitability. 
The introduction into other markets is often postponed as lower profit margins make these countries 
less interesting. With an obligation for mutual recognition for EMA’s member states, Europe can be 
treated as one market. For each production site, two dedicated production lines can be constructed. 
The planning horizon is set to three years divided into months i.e. 36 time periods. The parameters 
in Table 4.1 come from the case company. The maximum number of lines simultaneously under 
construction is given by the chosen contractor and each line takes 3 months to construct. The target 
capacity of a new line is 500,000 units per month. The validation volume is set to 100,000 units for 
all markets. Validation time is usually 6 months. The total shelf life of a formulated drug is two 
years, but given that a significant remaining shelf life is needed further downstream, shelf life is 
here set to 12 months. The discount rate is 0.5 % per month. The holding cost is set to 0.2 per unit 
per month mainly reflecting the perishability of the drug and the API cost is set to 2 € per unit. 
Construction, production, transportation and validation costs are found in Table 4.2. Typically, 
validation costs are higher for sites in less developed countries where production costs are lower. 
Market data can be found in Table 4.3. The market diffusion of the new drug is modelled with an 
s-shaped function as described in Cook (2006), which reaches peak demand after 10 months while 
50 % of peak sales are reached after 5 months. Note that full demand for all markets corresponds to 
full utilization of the effective capacity for four production lines. The demand represents the best 
possible demand scenario, which supply should cover. The supply chain filling effect is given as 3 
months peak demand. The authorization dates are provided by the authorities. 
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Table 4.1: Scalar parameters. 
Parameter Abbr. Value Unit 
Construction time CT 3 Months 
Cost per production 
line  
F 2500 k€ 
Max # of lines under 
construction 
MC 2 - 
Capacity per line CAP 500.000 Units 
Validation volume V 100.000 Units 
Validation time VL 6 Months 
Shelf life SL 12 Months 
Discount rate D 0.5 
% per 
month 
Holding cost H 0.2 
€ per unit 
per month 
Scrap cost W 0.5 € per unit 
API cost APIC 2 € per unit 
 
Table 4.2: Production site specific parameters.  
Production 
site 
Production 
cost per 
period 
[k€] 
Transportation costs to 
market per unit [€] 
Validation costs to 
market [k€] 
US EU JP US EU JP 
1 1000 1.1 1.8 2.2 750 1750 1500 
2 1100 1.5 1.2 1.4 1500 1250 1250 
3 850 2.5 2.8 1.2 2000 1500 1750 
 
To model ramp up, the three functions introduced in section 3 are used with ramp ups lasting 6 
months if the lines were fully utilized (to within 99.7 % of the target capacity for the sigmoid and 
time constant function). We demonstrate how we find the linear approximation curves in Appendix 
B.  
These problem instances have 540 binary and 871 continuous variables and 2550 constraints. 
The model takes up to 100 seconds to solve to optimality with CPLEX v.12.5 on a Dell Latitude 
E6400 with an Intel Core 2 P8400 2.27 GHz processor and 4 GB ram. 
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Table 4.3: Market parameters. 
Markets 
Contribution 
margin 
[€ per unit] 
Peak 
demand 
[units] 
Authorization 
date [Month] 
US 66 750,000 12 
EU 60 750,000 13 
JP 54 500,000 16 
 
4.5.1. The model as decision support tool 
To illustrate how the model can be used for decision support, a Gantt chart representation of which 
lines to open in which sites is given in Figure 4.8. Here construction and ramp phases for the 
individual lines are shown. The period in which a site submits the validation material is represented 
by the circled market abbreviations. Lines are opened when needed either to obtain validation 
before market authorization or to cover the increasing demand. The underutilization of lines is 
reflected in the long time required for completing the ramp up in some sites.  
The operations plan produced by the model which shows target and effective capacity, 
production volume, inventory and shipping profiles as well as market launch dates is shown in 
Figure 4.9 for the sigmoid ramp-up function. Only the first 24 months are shown as the system has 
already reached steady state at this point. It is clearly seen how production is ramped up with each 
line following an s-shaped curve. Prior to each market launch, inventory is build up to cover the 
supply chain filling effect. Inventory is also used to postpone the opening of the last line. The 
substantial amount of unused effective capacity and the resulting longer ramp-up lengths in Figure 
4.8 and Figure 4.9 illustrate the necessity to model ramp up based on cumulative production volume 
rather than time.  
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Figure 4.8: Overview of market validations, construction and ramp-up phases for each line and 
site. 
 
 
Figure 4.9: Target and effective capacity, inventory and shipping profiles over the planning 
horizon using the sigmoid function for modelling ramp up. 
 
The model solution can also be compared to the current approach prevalent in the industry. 
Capacity expansion is often done via one project with a single company responsible for constructing 
the new lines and completing the project within a year. When we add a constraint which does not 
allow the construction of new lines after month 12 to mimic this operational policy, we obtain the 
solution shown in Figure 4.10. Here the length of ramp up is much longer. The additional cost lead 
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to a 7 million € drop in the company’s profits showing the value of postponing the opening of some 
lines.  
 
 
Figure 4.10: Comparison to the current industry approach. 
 
 
Figure 4.11: Market validations, construction and ramp-up phases for each line and site, if two 
validations per market are enforced. 
 
As a decision support tool, the model allows managers to quickly perform what-if analyses. 
Managers in the pharmaceutical industry are for example often interested in the impact of having 
multiple sites validated for each market. This is often done to reduce the risk of supply shortage, if 
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production in one site is temporarily disrupted. Figure 4.11 shows the result when we enforce two 
validations per market. Site 2 is validated for Japan before Site 3, allowing the construction of the 
line in site 3 to be postponed by 4 months.  
 
Table 4.4: Analysis of reducing the effective shelf life. 
 
 Effective shelf life length [months] 
8 7 6 5 4 3 2 
Profit [m$] 2249 2249 2249 2249 2247 2242 2238 
Scrap [1000 units] 0 2.4 46.80 231.2 669.4 661.2 1601 
Inventory [1000 units] 20810 20810 20920 18760 17290 13550 9604 
 
Companies might want to or have to deliver products with a longer remaining shelf life to 
customers, effectively reducing the shelf life available to them. Table 4.4 shows the results for 
different lengths of effective shelf life. Here profits drop consistently. Scrap increases as some 
production for validation and ramp up is necessary, which afterwards have to be thrown out. For 3 
months of effective shelf life, the solution structure changes, causing higher production and 
transportation cost and lower profit without increasing scrap.  
 
4.5.2. Comparison between time-dependent and volume-dependent ramp up 
Having shown that our approach leads to longer ramp ups than the 6 months needed under full 
utilization, we now demonstrate why this is a better approach to modelling ramp up. For this we 
compare our modelling approach referred to as volume-dependent ramp up with the common time-
dependent ramp up. For time-dependent ramp up, Eq. (11), (12) and (13) are replaced with 
, ' 1 , '
'
, ,l li t t t i t
t t
CAP l i t  

   . Let li  be the time period in which line i in site l is opened i.e. 
l
i t   if , 1
l
i t   and let 
l
i  be the time period in which line i in site l reaches target capacity. Then 
the vectors describing line openings and last ramp-up period in Table 4.5 are given as 
1 1 3
1 2 2[ , ,..., ]    and 
1 1 3
1 2 2[ , ,..., ]   . Table 4.5 shows a comparison between time-dependent and 
volume-dependent ramp up for the power function. 
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Table 4.5: Comparison between volume- and time-dependent ramp up. 
 
Solution 
Total capacity over the 
planning horizon 
Average 
utilization Line opening 
Last ramp-up 
period 
Volume-
dependent 
[4,17,5,0,8,0] [9,22,10,0,15,0] 48,019,175 93.86 % 
Time-
dependent 
[4,18,5,0,8,0] [9,23,10,0,13,0] 49,143,528 88.03 % 
  
 
 
Figure 4.12: Illustration of the problem with modelling ramp up as time dependent. 
 
As can be seen in Table 4.5, time-dependent ramp up provides more capacity over the planning 
horizon than volume-dependent. The difference is caused by the predefined effective capacity 
increase of time-dependent ramp up, which does not require any production. In practice this leads to 
large jumps in planned production volumes as illustrated in Figure 4.12. Here, Site 3’s production 
steadily increases for volume-dependent ramp up, while production volume goes from 0 to 400,000 
units in one month for time-dependent ramp up. This corresponds to leaving production lines 
unused and then producing large production volumes right before market launch. This would not be 
possible in reality. For this site, ramp up is faster than product diffusion, requiring only smaller 
volumes to be produced, which explains why the ramp up last 8 months.  
 
4.5.3. Influence of the ramp-up functions 
The influence of the shape of the ramp-up functions is shown in Table 4.6, which compares the 
three functions used here. As both the sigmoid and the time constant function reach a relatively high 
effective capacity faster, lines can be opened up later than for the power function and the ramp-up 
period can be extended. This is shown in Figure 4.13, in which the shape of each ramp-up function 
is clearly visible. Though lines are opened later, the model with the time constant function still 
creates a higher total effective capacity for the entire planning horizon. Clearly, the ramp-up 
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function has a direct impact on the profit of the market launch. The results illustrate the importance 
of using the correct ramp-up function for planning ramp up. If used incorrectly, the time constant 
function would lead to lines that are opened too late, whereas the power function loses money on 
unnecessary early openings. To avoid delayed market launch or premature investments, the ramp-up 
capabilities of the company should be thoroughly investigated, before planning is undertaken. 
 
Table 4.6: Results for the different volume- and time-dependent ramp-up functions. 
Ramp-up 
function 
Solution 
Total effective capacity 
over the planning horizon 
Profit 
[m€] 
Line opening 
Last ramp-up 
period 
Power function [4,17,5,0,8,0] [9,22,10,0,15,0] 48,019,175 2247.7 
Sigmoid 
function 
[4,19,5,0,8,0] [11,24,12,0,19,0] 49,457,912 2249.4 
Time constant 
model 
[6,20,7,0,10,0] [13,25,14,0,21,0] 49,904,495 2256.5 
 
 
Figure 4.13: Ramp up of effective capacity for all volume-dependent ramp-up functions. 
 
4.5.4. Length of ramp ups and the value of shortening ramp ups 
In addition to the shape of the ramp-up curve, the length of the ramp-up process is important as it 
directly affects the opening decisions. This is shown in Table 4.7, which shows the results for 
different ramp-up lengths. The value of the lengths refers to the duration required if the line is fully 
utilized. Smaller profits result for larger ramp-up lengths. The decision of when to open lines also 
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changes, indicating that an underestimation of how long ramp up takes would lead to lines being 
constructed too late. The solutions for the different ramp-up functions converge as the length is 
reduced. However, the decisions on when to open the lines continue to be different.  
The preparation of production for a new ramp up is important for how fast the ramp up can be 
completed (Schuh et al., 2005). Investing in e.g. training of personnel or process improvements can 
help reduce the ramp-up length. Table 4.7 illustrates, that shortening the ramp-up process has a 
direct value as investments could be postponed. Reducing the ramp-up length of e.g. the power 
function from 4 to 3 months would generate an extra 3 mill € in profit, which forms a strong 
argument for investing ramp-up preparation measures.  
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Table 4.7: Results for the different ramp-up functions with different ramp-up lengths. 
 
Ramp-up function 
Ramp-up length = 2 
months 
Ramp-up length = 3 
months 
Ramp-up length = 4 
months 
Ramp-up length = 6 
months 
Profit 
[m€] 
Line openings 
Profit 
[m€] 
Line openings 
Profit 
[m€] 
Line openings 
Profit 
[m€] 
Line openings 
Power function 2253 [5,19,6,17,0,0] 2253 [5,19,6,0,9,0] 2249 [4,18,5,0,8,0] 2248 [4,17,5,0,8,0] 
Sigmoid function 2257 [6,21,7,0,10,0] 2254 [5,20,6,17,0,0] 2253 [5,19,6,17,0,0] 2249 [4,19,5,0,8,0] 
Time constant 
model 
2258 [6,21,7,18,0,0] 2258 [6,20,7,19,0,0] 2258 [6,20,7,19,0,0] 2256 [6,20,7,0,10,0] 
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4.6. Conclusion and further research 
In recognition of the fact that production systems are frequently not fully utilized during ramp up, 
this paper focuses on capturing the effective capacity during ramp up better. Ramping up a new 
process represents a learning process in which experience is gained as more units are produced. For 
not fully utilized manufacturing systems, a time-dependent ramp function would overestimate the 
effective capacity available. Instead we suggest a method for linking effective capacity to 
cumulative production volume. We illustrate the value of this methodology by developing a 
computationally effective model for making capacity expansion decisions for secondary 
pharmaceutical production. Here slow demand diffusion, time-phased market launch and early 
production for validation leaves new production lines temporarily unutilized. We propose a MILP 
model, which also considers industry aspects such as process validation  and limited shelf life.  
In an industrial case study the model is used as a decision support tool with three different ramp-
up functions. The results are compared to the current approach in the industry, showing the value of 
postponing the construction of production lines. The model allows managers to perform what-if 
analyses such as enforcing multiple validations for each market and reducing the effective shelf life, 
which both cause changes in the opening decisions. It is demonstrated how time-dependent ramp up 
leads to an overestimation of effective capacity and can generate capacity expansion plans, which 
make on-time market launch impossible. The different ramp-up functions are compared, showing 
the importance of investigating the ramp-up capability of a company before planning any ramp ups. 
Reducing the length of the ramp-up process leads to significant savings. This is also indicative of 
the value of possible investments in ramp-up preparation measures.  
The method for capturing effective capacity as a function of cumulative production volume is 
demonstrated for secondary pharmaceutical production. The number of advanced drug delivery 
systems is growing (Sezer, 2012), so we expect the methodology developed here to become even 
more relevant for the industry. However, our modelling approach is also suitable for describing 
ramp up in other demand-driven industries with slow demand diffusion.  
Two extensions to the work presented in this paper will be subject of our future research. The 
first relates to a more advanced representation of learning. The second to the consideration of 
uncertainties inherent in the market launch phase. By having several new production lines in a 
network starting up in succession, companies are normally able to transfer knowledge from line to 
line or site to site to shorten the ramp up. Though these effects have been reported in the literature, 
no work has tried to quantify it or use it in a planning methodology. Especially for lines in the same 
production site, knowledge transfer plays a significant role.  
The current trends in the pharmaceutical sector lead towards more uncertainty in market 
authorization dates, in allowed prices and in approved claims. An inclusion of these uncertainties is 
crucial in planning for effective market launches.  
 
   Chapter 5 
89 
 
Chapter 5: Conclusion and future research 
 
In this dissertation, the new product introduction process in the pharmaceutical industry is treated. 
Focus is given to large pharmaceutical companies that both develop and manufacture novel phar-
maceutical products. Several trends challenging the industry are identified, and the increasing diffi-
culty of bringing new drugs to market faster or even at the same pace is singled out as the key prob-
lem for the industry. Attention is given to the management of companies’ supply chain operations, 
which has so far not prioritized the crucial operations around market launch, even though this di-
rectly impacts TTM. Developing new planning methodologies for operations in this part of the new 
product introduction process is the main aim of the thesis.  
 
In this chapter, we conclude by revisiting the research questions posed at the beginning of this the-
sis. A summary and the main findings of the previous chapters are here used to answer each ques-
tion in turn.  
 
5.1. Conclusion 
 
 
 The new product introduction process is analyzed in chapter 2. In a case study from a pharma-
ceutical company, managers from all functions are interviewed on their role in the new product in-
troduction process and their relation to other functions. From the interviews, key tasks and their 
interrelationships are identified from which a project network representation and a precedence rela-
tionship between tasks of the new product introduction process are constructed. The discussions 
with the managers also help in forming observations on the central challenges facing the industry. 
Several companies are used for validation, confirming the findings and adding further insights. 
Through literature review of the planning challenges in the new product introduction process, sev-
eral planning areas are subsequently identified. The identified planning areas consider a fairly ag-
gregate decision level and most contributions are confined to these areas, attempting only to pro-
pose different model formulations or improve decision techniques rather than expand the range of 
decisions supported. Five observations about the remaining challenges in new product introduction 
are identified, which could lead to shorter TTM. The first observation is that companies are slow to 
implement the advanced planning methodologies found in the literature, whereas the next two ob-
servations relates to expansion of the planning domain for pipeline management. These extensions 
are difficult due to the complexity and lack of transparency in the system of approvals with a multi-
RQ1: What are the challenges facing the pharmaceutical industry during the new product 
introduction process in reducing time-to-market? 
Conclusion and future research  
90 
 
tude of authorities. The two remaining observations appear to be more fruitful lines of research as 
they point to the lack of a planning methodology for planning operations up to market launch. Sur-
prisingly, no well-defined techniques are found to help determine production volumes or inventory 
levels. These decisions are getting harder to make due to rising uncertainty and they will require 
more attention in the future if companies are to cover demand at market launch. On the supply-side, 
ramp-up effects present in the introduction of new drug delivery systems are making capacity plan-
ning of secondary pharmaceutical production more complex, requiring more attention if TTM 
should be kept low. These two observations form the direction for the next research questions. 
 
 
 
 Planning of operations for market launch of new pharmaceutical drugs is treated in chapter 3. 
Three key uncertainties from the market authorization process are identified; the length of the pro-
cess, the risk of a forced label change and uncertain reimbursement levels, which is handled through 
demand uncertainty. These uncertainties are captured in a two-stage stochastic MILP model, which 
encompasses all stages of secondary pharmaceutical production. Several launch preparation deci-
sions, which have to be made up front, are found through the model. We demonstrate how the struc-
ture of the problem can be used for modeling the scenarios in a very effective way and how uncer-
tainty over time can be resolved without the need for multi-stage programming. Based on a case 
study from a typical pharmaceutical company, an extensive numerical test of 100 different instances 
is investigated.  
 The expected delay of a market launch represents TTM, as expected delays reflect the lost peak 
revenue of a longer TTM. Trading off this with several other costs, the model supports decision 
making for the launch preparation decisions such as required API volume, volume outsourced to a 
CM and the PPM volume purchased. Our model prioritizes resources such that market launch de-
lays predominantly take place in less profitable markets. Considering all instances, delays are how-
ever unavoidable. Furthermore, we find that risk packaging, i.e. having market-specific finished 
product on inventory prior to market authorization, is only needed for large markets, when capacity 
restricts covering the market in one period.  
 Further insights are gathered by changing the supply chain configurations and testing several 
operations policies. We found, that PPM suppliers should be found based on their speed rather than 
cost, as lead time was found to have a far greater impact on expected delay and total cost than sup-
plier cost. By changing the sales price to reflect drugs with higher development cost and higher 
benefit for the patients, it was found that drugs with a higher price such as e.g. the fast growing 
group of biologics can also be described with this model. Additionally, our model outperforms any 
strict risk packaging policies as it better reflect how much of the product should be risk packaged.  
RQ2: How can pharmaceutical companies better plan operation in preparation of market 
launches while considering some of the unique uncertainties present around the launch? 
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 The real benefit of our approach is demonstrated by a comparison with the current industry ap-
proach. Currently managers estimate the needed API volume through a worst case rule which leads 
to overstocking. The amount of API found by our approach is significantly smaller, and our ap-
proach leads to a 14 % lower cost due to lower API production costs, holding costs and scrapping 
cost. Furthermore, our results indicate that oversizing the API inventory, which the industry has 
done excessively, leads to more risk affine managers in terms of higher risk packaging. Expected 
delays of market launch are however shorter for the industry approach. 
 Finally, we demonstrate how robust optimization can be used to balance TTM and total cost. 
Since any delay has a high cost, a delay in just one scenario leads to a cost significantly higher than 
that of other scenarios. This difference leads to large variations in the total expected cost. By using 
robust optimization with the first order upper partial mean to reduce this variation, a consistent re-
duction of the expected delay i.e. TTM at a limited increase in cost without necessarily overstock-
ing API is found. With this Pareto relationship between total cost and lost peak revenue, managers 
can find their acceptable TTM and cost combination. 
 
 
 
The fourth chapter focuses on improving modeling of ramp up in capacity planning for second-
ary pharmaceutical production. For demand-driven industries, full utilization is not always required, 
but lowering production also reduces the experience gained with the new product and the projected 
increase in effective capacity is not attained. This leads to an overestimation of the ramp-up effect 
in current time-dependent ramp-up models. Instead, an effective method for capturing ramp up as a 
function of the cumulative production volume is presented. It is demonstrated on secondary phar-
maceutical production, which due to slow demand diffusion and the required production of a valida-
tion volume ahead of market launch, sees equipment utilization lowered at times. The planning 
model using the improved ramp-up modeling is used to ensure product availability as new produc-
tion lines have to be constructed and ramped up prior to market launch. Industry specific character-
istics such as validation of production for each market and limited shelf life are also considered in 
the model.  
A case study from the industry is presented, and the model is shown to provide both capacity ex-
pansion plans as well as production and inventory profiles over the market launch phase. To assure 
product availability, planning is based on the highest demand scenario. Results clearly show both 
the original shape of the used ramp-up function as well as the extended ramp-up length due to un-
derutilization. A comparison with the current practice of building all lines within the first year 
demonstrates the value of a more nuanced approach to capacity planning, which allows the post-
ponement of several line openings. Different what-if analyses can be carried out such as enforcing 
RQ3: How should pharmaceutical companies plan secondary production capacity to reflect 
ramp up of effective capacity on underutilized production lines such that product availability at 
at market launch is ensured?     
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multiple validations for each market to ensure supply in case of disturbances. Experiments with 
different effective shelf lives also show the model’s functionality as a decision support tool.  
Several insights into ramp-up management are also gathered. The overestimation of the often-
used time-dependent ramp up is demonstrated and it is likely that on-time market launch with this 
representation is not possible. As secondary production ranges from production of pills to syringes 
or even more complex drug delivery systems, three different ramp-up curves found in the empirical 
literature are compared; the power curve, the s-shaped curve and the exponential curve. Faster ramp 
ups (exponential curve) allow for the opening of new lines to be delayed compared to slower ramp 
ups (power curve). This effect is less pronounced if the ramp-up length is reduced, but a difference 
in the expansion plan is still evident, demonstrating the value of faster ramp up. By reducing the 
length of ramp ups, the value of investing in ramp up preparations is shown. Assuming that the dif-
ferent types of secondary production resembles equivalent production in other industries, we sus-
pect that the highly automated production of pills will exhibit an exponential ramp-up curve, 
whereas more advanced drug delivery systems would resemble the s-shaped ramp-up curve of the 
labor intensive automotive assembly. 
 
In this thesis, the current planning methodology for new product introduction in the pharmaceu-
tical industry is expanded by including two models into the planning hierarchy shown in Figure 1.3. 
The first model for supporting a series of launch preparation decisions while considering 3 different 
uncertainties is presented in chapter 3. As seen in Figure 5.1, this model would support decision 
making for aggregate production volumes which are send to the subsequent MRP process based on 
input from capacity and demand planning. Capacity planning is extended in chapter 4, where a far 
more accurate model for capacity in secondary production is developed (cf. Figure 5.1). The model 
focuses on capacity planning for introduction of a new drug delivery system and captures ramp up 
of effective capacity better, while considering validation and limited shelf life. With better capacity 
planning, the quality of the launch preparation model is increased. Central for both models is the 
use of industry-specific characteristics to better capture problems. The lower planning levels of 
MRP, production and demand fulfillment remain unchanged. 
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Figure 5.1: Overview over the contributions of this thesis to operations prior to market launch. 
 
5.2. Future research 
In this final section, possible future research is outlined both to the present case of planning opera-
tions in the last stage of new product introduction in the pharmaceutical industry and more general 
to research topics in operations management and planning. With new trends leading to a more com-
plex and uncertain end phase of the new product introduction process, the old paradigm of exces-
sive production to inventory based on loose estimates should be replaced by more complex method-
ologies, which consider both dynamics of market launch and industry-specific characteristics. In 
this thesis, two contributions to this area are presented, but there are still many possibilities for ex-
panding this work. 
The need for planning of operations in the last phase of new product introduction to ensure prod-
uct availability at market launch and keep TTM low is clearly demonstrated by our results in chap-
ter 3. Our approach was demonstrated for several different instances and supply chain configura-
tions. Expanding the supply chain to consider a larger network with multiple PPM suppliers and 
CMs in more detail would allow for better uncovering of their role in operations prior to market 
launch. Further insights into which stage(s) should be outsourced up to market launch and how mul-
tiple suppliers should be managed could still offer more insight into managing operations before 
and during market launch. The impact of introducing a new product into an existing multi-product 
pharmaceutical supply chain has already been investigated (cf. chapter 2 and 3). However, these 
contributions do not capture the uncertainty of market launch and can hence only give an aggregat-
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ed picture of the impact of a new product in the supply chain. For larger cases, computational speed 
may become an issue requiring new solution procedures. Here, hierarchical modeling could be a 
good way to split the problem up in e.g. a pre-launch model and a launch model, similar to Özer and 
Uncu (2013). One simple approach of cautiously estimating the required API volume was treated in 
chapter 3, but more elaborate heuristics might also be developed to cover more of the launch prepa-
ration decisions.  
By using the structure of the problem, we were able to capture three separate uncertainties in one 
model and still have an acceptable computational complexity. This shows that there are still a lot of 
opportunities to develop new methodologies for modeling several uncertainties in a tractable way, 
rather than just focusing on a single source of uncertainty. When considering more uncertainties 
simultaneously, the correlation between the outcomes of these uncertainties is obviously a central 
point. In chapter 3, independence was assumed between the uncertainties. We believe this is a fair 
assumption, but certain interdependence cannot completely be ruled out. Interdependence between 
e.g. the reimbursement levels in different markets is very likely as reference pricing is used. As dis-
cussed in chapter 2, this is however difficult to capture due to the lack of transparency and data. 
Other interdependencies and correlations can also be difficult to identify and hence model. Robust 
optimization was used as a risk management approach in chapter 3 as a way of trading off TTM and 
total cost. Other risk management techniques such as conditional-value-at-risk could not be imple-
mented due to our modeling approach for the scenarios. For a system with several risks, there is 
generally much research left to both find ways to model it and ways to manage it.  
The value of better capturing industry characteristics such as improved modeling of production 
ramp up, validation and shelf life are demonstrated in chapter 4. It is possible to add further aspects 
of pharmaceutical production to models. Validation volumes could be more detailed if enough in-
formation about the new drug is available to calculate the exact required amounts. As distribution of 
a drug takes varying length of time for different market and thereby consume different amounts of 
the shelf life, market dependent shelf life should perhaps be considered. Russian reports of drugs 
being six months in transit show that distribution time can sometime be a significant length of time. 
Lower planning levels could also consider document flows and lead times directly as these often at 
this level are determining the lead time of pharmaceutical production. Several possible expansions 
of our approach to model ramp up could also be interesting. With several new identical production 
lines, knowledge transfer is an obvious way to reduce the ramp up length. Currently this is already 
being practiced in the industry. After ramp up of the first line, the production team from that line is 
sent to other lines to teach other teams about the new processes, i.e. a one-way transfer of 
knowledge. This could lead to the creation of lead- and follow-plants as seen in the automotive in-
dustry. Two-sided knowledge transfer could also be considered for two lines being ramped up sim-
ultaneously in the same plant. If knowledge is transferred, their combined experience i.e. combined 
cumulative production volume could potentially be used to describe the ramp-up process. A com-
pletely different way to shorten ramp up, when several identical lines are considered is to instigate 
friendly competition between plants for who can produce the most. Finally, the contractor team 
building the lines might also gain experience leading to shorter construction time of new lines.  
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Throughout the thesis buildup of inventory prior to market launch is discussed. However, we 
have thereby only considered inventory as a buffer to balance supply and demand over the planning 
horizon. Since demand uncertainty of new pharmaceutical products is high due to the lack of histor-
ic data to base forecasts on, safety stocks are usually carried to buffer against short term demand 
variations. Safety stock placement has already been covered in the literature and can also cope with 
non-stationary demand (cf. Graves and Willems, (2008). Safety stock placement however only con-
siders lead times, service level and pooling effects. This leaves room for further research of how 
additional uncertainties or limited shelf life might influence such models.  
With high profit margins on new pharmaceutical drugs and increasing uncertainty, further inves-
tigation into the use of flexibility for the pharmaceutical industry could be very interesting as an 
alternative to risk management. The industry is already embracing several methods of creating flex-
ibility such as e.g. contract manufacturing. Recently, the industry has also been trying to expand the 
range of measures to create flexibility by e.g. improving production planning, increasing labor flex-
ibility and integrating suppliers (McKinsey, 2011). There is however not enough research on how to 
use flexibility in operations planning and especially how to best comprise an appropriate mix of 
different flexibility measures. Several of our contact companies are e.g. considering using post-
ponement to gain flexibility around packaging. Some are considering using partial packaging of 
products in combination with keeping multiple versions of the labels on-hand before the final mar-
ket authorization. They can then use the label which is authorized. This will keep TTM low while 
still giving them the possibility of getting stronger claims authorized. But it is also a costly ap-
proach.  
Where it is clear that good planning can help keeping TTM down, only new technologies in 
combination with adapted regulatory guidelines seems to be able to provide significant reductions 
in TTM. Such technologies, which could also help shorten clinical trials, could be improved com-
puter analyses to provide predictive toxicology of new chemical compounds or development of bi-
omarkers to better prove a drugs effect statistically (FDA, 2004). Another initiative that might im-
pact manufacturing significantly is the immergence of continuous production to replace the current 
batch production. Continuous production, enabled through safe continuous process monitoring, 
could lead to faster process design and smaller dedicated production facilities without the need for 
lengthy setups and hence reduce throughput times of the API dramatically. Though these new tech-
nologies could cut TTM significantly, their development is slow and it seems that large reductions 
in TTM are not imminent. Until then it therefore seems that incremental improvements in e.g. sup-
ply chain planning as demonstrated in this thesis is the most viable option for shortening new prod-
uct introductions in the pharmaceutical industry. 
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Appendix A 
In this appendix, we show how the ramp-up curves describing effective capacity as a function of 
time can be re-written to a function of effective capacity over cumulative production volume. This 
better represents the underlying learning process and captures the experience gained.  
 
Power function 
For the power function, the effective capacity (y) as presented in Risse (2003) can be expressed as a 
function of time (t): 
(A1)y t   
To obtain capacity as an expression of the cumulative production volume, an expression for the 
cumulative production volume (x) as a function of time is first found by integrating (A1) from 0 to t 
to find the cumulative production volume given as an expression of time. 
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and find the effective capacity as a function of cumulative production volume by: 
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Sigmoid function 
For the sigmoid function, the effective capacity (y) can be expressed as a function of time (t): 
( )
(A5)
(1 )b t
a
y
c e  

   
To obtain capacity as an expression of the cumulative production volume, an expression for the 
cumulative production volume (x) as a function of time is first found by integrating (A5) from 0 to t 
as above.  
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To obtain the capacity as a function of the cumulative production volume, we first isolate t  
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and insert the expression into (A5) 
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For large values of c, 
1
1
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c
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Time constant model 
For the time constant function, it is not possible to find an analytical expression as we cannot isolate 
t in ( 1)tx k t r t e      . Instead we use the Newton-Raphson method to numerically approximate 
the curve as described in both Atkinson (1989) and Jensen and Bard (2003). Here t values can be 
found by iteratively approach the true value through the step size: 
1
( )
0 (A10)
'( )
n
n n
n
f x
x x n
f x
   
 
With this, we can approximate our function for any value. Illustrations of the resulting function are 
based on 200 different points.  
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Appendix B 
Finding a piecewise linear curve to approximate the functions is a fitting problem. We instead 
simply approximate the curve with a number of tangents, which suffices as only a few function 
values will ultimately be used in the model. This approach, however, leads to a slight 
overestimation. For each function, we first find the cumulative volume at which target capacity is 
reached. The tangent and respective cumulative volume x crossing this point are then found. 
Hereafter seven points are found within the interval [0; ]x  given as 
{0;0.1;0.2;0.3;0.4;0.6;1.0}  rx x  . This distribution is chosen since the derivatives change 
substantially in the first part of the curve. With the points determined in this way, the maximum 
overestimation is small. As the curves are used as linear constraints in the model, adding additional 
points adds little to the complexity, but also adds little in terms of solution accuracy. The slope, 
denoted CRr, is found as ( ) /r rCR y x x    and the intersect with the vertical axis denoted CLr is 
given as ( )r r r rCL y x CR x   . As the tangents to the origin for the power and sigmoid functions 
would have CL1 = 0, we use an x1 slightly larger than zero to obtain an effective capacity in period 
1 which is larger than zero. The parameters for the linear curves approximating the ramp-up 
functions are found in Table B.1, while the linear curves used as well as the piecewise linear curves 
approximating the ramp-up functions are shown in Figure B.1. 
 
Table B.1: Parameters for the linear approximation of the ramp-up functions.  
Curve 
Power function Sigmoid function Time constant model 
CR CL CR CL CR CL 
1 1.949 3,200 2.344 4,600 2.429 109,400 
2 0.817 28,100 0.875 155,300 0.415 250,300 
3 0.674 45,400 0.327 311,600 0.192 327,000 
4 0.601 60,400 0.122 407,400 0.104 378,100 
5 0.554 74,000 0.046 457,100 0.060 414,100 
6 0.494 98,700 0.006 491,700 0.022 457,900 
7 0.427 141,900 0.000 499,700 0.003 490,600 
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Figure B.1: Linear tangents approximating of the volume-dependent ramp-up curve for the pow-
er, sigmoid and time constant functions (left) and the resulting piecewise linear curve (right). 
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API Active Pharmaceutical Ingredient 
C1-4 Clinical trial, number 1-4 
CM Contract Manufacturer 
EMA European Medicines Agency 
FDA Food and Drug Administration 
GMP Good Manufacturing Practice 
IND Investigational New Drug application 
MILP Mixed Integer Linear Program 
MRP Material Requirements Planning 
NDA New Drug Application 
PC Pre-Clinical trials 
PPM Printed Packaging Material 
RQ Research Question 
RFID Radio-frequency identification 
SME  Small and Medium-sized Enterprises 
TTM Time-to-Market 
 
